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Systematic variation of membrane anchor, spacer and pharmacophore building blocks leads to an
optimisation of the inhibitory effect of tripartite structures towards BACE1-induced cleavage of the
amyloid precursor protein (APP).
Introduction
Alzheimer’s disease (AD) is the most common cause of demen-
tia and represents a growing burden for aging societies.1 In
2006, 26.6 million people were estimated to be affected world-
wide by this neurodegenerative disease and projection forecasts
the number of AD patients to rise to over 100 million in 2050.2
According to the amyloid cascade hypothesis,3,4 accumulation
and aggregation of amyloid β-peptides (Aβ-peptides) in the brain
plays a crucial role in the development and progression of AD.
Aβ-peptides are produced by sequential proteolytic cleavages of
the amyloid precursor protein (APP) executed by two mem-
brane-associated enzymes called β- and γ-secretase. The trans-
membrane protein aspartyl protease β-site APP cleaving enzyme
1 (BACE1) (also called Asp2 or memapsin2) was discovered
and cloned by several groups in 1999.5–9 Subsequently, BACE1
was shown to represent the primary β-secretase activity in cul-
tured cells and in vivo.10 BACE1 cleaves APP in the lumenal/
extracellular region to release a soluble, extracellular N-terminal
fragment (sAPPβ).11 The residual membrane-tethered C-terminal
fragment C99 is subsequently cleaved by γ-secretase to generate
different Aβ-peptides and the APP intracellular domain (AICD).
BACE1 represents a potential therapeutic target for reducing the
formation of Aβ-peptides. Several BACE1 inhibitors have been
reported.12–15 BACE1 appears to have diverse substrates and
important physiological functions. Therefore, very careful
dosing of BACE1-inhibiting drugs may be required to minimise
possible adverse side effects.10
Mature BACE1 cycles between the plasma membrane, the
endosomal compartment and the trans-Golgi network. The pro-
teolytic activity of BACE1 on wild-type APP appears to be
mainly confined to the endocytotic pathway16,17 and can be
increased by stimulating BACE1 internalisation.18 Therefore, an
efficient BACE1 inhibitor should be either membrane-permeable
or targeted to the membrane to become available in the endo-
somes. Lipid rafts, liquid-ordered membrane domains enriched
in cholesterol and sphingolipids,19,20 appear to be important for
BACE1 cleavage of APP. BACE1 has been detected in lipid raft
fractions21 and reduction of cholesterol was shown to decrease
cellular Aβ-production.22,23
In order to achieve high local concentrations of BACE1
inhibitors in designated subcellular regions,16 we have reported
the “tripartite structure” concept in 2005.24 Tripartite structures
are assembled by covalent coupling of BACE1 inhibitors with
membrane anchors via suitable spacers. The spacer is designed
to keep the inhibitor at an appropriate distance from the plasma
membrane. The membrane anchor should bind the tripartite
structure preferentially to the lipid raft domains of the membrane.
Thus, an enrichment of the tripartite structure in the lipid rafts is
achieved with “raftophilic” membrane anchors (Fig. 1).
Tripartite structures are rapidly internalised by endocytosis
and inhibit BACE1 much more efficiently than the correspond-
ing free inhibitors in cell lines and primary neuronal cell
culture.25,26 Moreover, they were reported to be active in vivo
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24, 28, 32, 47 and 48; log EC50 values and SD for all tested compounds;
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when injected stereotactically into the hippocampus of transgenic
APPsw/PSΔ9 mice.25
Herein, we describe the synthesis of novel tripartite structures
and extensive studies regarding their structure–activity relations
(SAR) in cell-based assays. In continuation of our previous
work,24–26 we report in detail the effect of different lipophilic
membrane anchors and spacers on the activity of tripartite struc-
tures carrying the prototype peptidic pharmacophore GL189.
Furthermore, we show that the potency of different non-peptidic
transition state BACE1 inhibitors is substantially improved by
incorporation into our tripartite structures.
Results and discussion
Tripartite structures were assembled from preformed building
blocks by solid-phase peptide synthesis. The building blocks,
used as pharmacophores, spacers and lipid anchors, were either
obtained commercially or synthesised as described below. For a
detailed SAR study by variation of lipid anchor and spacer
modules, we used the same peptidic substrate-based inhibitor as
before (GL189 = H-Glu-Val-Asn-Sta-Val-Ala-Glu-Phe-NH2).
27
Modifications of further literature-known BACE1 inhibitors,
obtained by de novo synthesis, provided additional building
blocks for solid-phase peptide synthesis.
The membrane anchor building blocks were obtained by esteri-
fication of lipidic alcohols, e.g. dihydrocholesterol (Dhc-OH)
with the protected amino acid Fmoc-Asp-OtBu (1) using 1-(2-
mesitylensulfonyl)-3-nitro-1H-1,2,4-triazole (MSNT) or N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride
(EDC·HCl) (Scheme 1). Cleavage of the tert-butyl esters 2a–j
with trifluoroacetic acid afforded the Fmoc-protected building
blocks 3a–j, suitable for solid-phase peptide synthesis.
Ideally, the inhibitor should be positioned by the spacer close
to the active site of BACE1 by keeping a similar distance from
the plasma membrane. Moreover, the spacer should not affect
the interaction between BACE1 and the inhibitor. We have
chosen oligoethylene glycol units as spacer modules due to their
low toxicity, high bio-compatibility, high stability and good solu-
bility under physiological conditions. To investigate the potential
influence of the chemical composition of spacer modules, the
aminomethylphenylacetic acids 5a and 5b were tested as alterna-
tive building blocks. Using the commercially available N-Fmoc-
ω-amino(oligoethylene glycol)carboxylic acids 4a–g or the
N-Fmoc-aminomethylphenylacetic acids 5a and 5b as building-
blocks, spacers of various lengths were prepared. The N-Fmoc-
protected carboxylic acids were directly suitable for solid-phase
peptide synthesis (Fig. 2).
The tripartite structures were prepared by automated solid-
phase peptide synthesis and purified by preparative HPLC (see
the Experimental section). The structures were supported by
mass spectrometry. Previous advanced NMR experiments
confirmed that the peptide synthesis proceeded without epimeri-
sation and single diastereoisomers were obtained.26 According to
HPLC analysis, the purities of tripartite structures generally were
higher than 99.9% (Table 1).
As described previously, the biological activity of the tripartite
structures was determined by measuring the concentration of
Aβ40 peptides secreted by cultured SH-SY5Y cells overexpres-
sing human wild-type APP695.26
Variation of the membrane anchor
The affinity of membrane anchors to lipid rafts depends on their
structural features. Therefore, we have studied the effect of
different membrane anchors on the efficiency of tripartite struc-
tures as BACE1 inhibitors in a cellular assay. Assuming that
amyloidogenic APP cleavage by BACE1 is dependent on lipid
Fig. 2 Building blocks for the spacer moiety of the tripartite structures.
Fig. 1 Tripartite structure concept. Anchoring of the pharmacophore
(BACE1 inhibitor) via an appropriate spacer to a raftophilic membrane
anchor leads to an increase of the inhibitor concentration in the proxi-
mity of the active site of BACE1 as both are located in the lipid rafts.
Scheme 1 Synthesis of membrane anchor building blocks 3a–j.
Reagents and conditions: (a) 1.1 equiv. Fmoc-Asp-OtBu (1), 1.0 equiv.
Dhc-OH (or Chol-OH, CnH2n+1OH (n = 14, 16, 18, 20, 22, 24, 26) or
oleyl-OH), 1.1 equiv. MSNT and 1.1 equiv. MeIm (or 1.5 equiv.
EDC·HCl cat. DMAP), CH2Cl2, rt, 4–52 h; (b) CF3COOH, CH2Cl2
(1 : 0.8–1.5), rt, 90 min, 3a: 71%, 3b: 61%, 3c: 67%, 3d: 64%, 3e: 76%,
3f: 68%, 3g: 92%, 3h: 70%, 3i: 80%, 3j: 65% (yields over two steps).
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 8216–8235 | 8217
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rafts, tripartite structures with very efficient raftophilic membrane
anchors should exhibit the highest potency. The tripartite struc-
tures 6a–j (Table 1 and 2) were synthesised using the membrane
anchor building blocks 3a–j (Scheme 1), the peptidic inhibitor
GL 189 and the 4Gl-3Gl-4Gl-3Gl-4Gl spacer module.
The spacer length was kept constant (approx. 89 Å, assuming
an extended conformation of the spacer) to have results compar-
able with existing data.26 The effect of 6a, 6c, 6d and 6j on the
generation of sAPPβ by HeLa cells overexpressing the Swedish-
mutant form of human APP was studied before at two concen-
trations (20 and 200 nM).25 The tripartite structure 6a with the
dihydrocholesteryl anchor was reported to be most potent. Com-
pound 6j with a cis double bond in the oleyl anchor was found
to be essentially inactive. Overall, the efficiency of different tri-
partite structures in BACE1 inhibition appeared to resemble their
degree of raft partitioning. In our previous study, cells expressing
Swedish-mutant or wild-type APP showed differences with
respect to the BACE1 inhibiting activity of tripartite structures
and the secretion of Aβ-peptides.26 Therefore, we conducted an
extensive comparative study of the activity of tripartite structures
with a range of different membrane anchors (long-chain lipid
alcohols ranging from C14–C26, dihydrocholesterol and choles-
terol) in SH-SY5Y cells overexpressing wild-type APP. To
compare the tripartite inhibitors on the basis of reliable EC50
values, each compound was tested in serial dilutions in at least
three independent experiments. In addition, for some compounds
the range of tested concentrations was varied between different
experiments to improve the accuracy of the determination of top
and bottom plateaus of the dose–response curves. Consequently,
not each single compound dilution depicted below was tested in
all three experiments. The dose–response curves for tripartite
compounds 6a–d, 6f and 6i are shown in Fig. 3.
The tripartite structures 6a and 6b with cholesterol and dihy-
drocholesterol as raftophilic membrane anchors reduced very
efficiently Aβ40 release into the cell culture medium. The EC50
values of 0.39 (log EC50 = −9.406 ± 0.182) and 0.74 nM (log
EC50 = −9.130 ± 0.035) calculated for 6a and 6b were substan-
tially lower than those of the tripartite structures 6c–i with long-
chain lipid alcohols as membrane anchors (Table 2). To evaluate
the statistical significance of the observed differences, we com-
pared the log EC50 values by one-way ANOVA and Tukey’s mul-
tiple comparison post-test. The difference in log EC50 between
6a (dihydrocholesteryl anchor, Dhc) and 6b (cholesteryl anchor,
Table 1 Analytical data for the tripartite structures 6a–j, 7a–q, 9–11,
13, 14, 16 and 18–20
No. Retention timea [min] Purityb [%] m/zc (calcd) m/zd (found)
6a 27.5 >99.9 2595.5516 2595.5529
6b 26.5 >99.9 2593.5360 2593.5356
6c 20.4 99.1 2421.4108 2421.4113
6d 22.3e >99.9 2449.4421 2449.4423
6e 24.7 >99.9 2477.4734 2477.4737
6f 27.2 >99.9 2505.5047 2505.5050
6g 29.4 99.9 2533.5360 2533.5346
6h 31.8 >99.9 2561.5673 2561.5669
6i 34.3 >99.9 2589.5986 2589.6005
6j 23.1e 99.9 2475.4577 2475.4522
7a 29.7 99.4 1783.0886 1783.0863
7b 29.2 99.9 1854.1257 1854.1267
7c 30.0 99.9 1871.1410 1871.1423
7d 27.8 >99.9 1898.1519 1898.1530
7e 27.9 >99.9 2057.2415 2057.2411
7f 29.8 97.8 2047.2459 2047.2499
7g 27.1 >99.9 2101.2677 2101.2650
7h 27.6 >99.9 2118.2830 2120.0g
7i 28.2 >99.9 2145.2939 2145.2938
7j 19.5f >99.9 2295.3310 2297.4g
7k 20.1f 99.4 2295.3310 2295.3295
7l 29.1e >99.9 2189.3201 2189.3208
7m 29.0 >99.9 2223.3507 2223.3509
7n 27.5 >99.9 2260.3572 2260.3574
7o 27.7 99.1 2436.4621 2436.4628
7p 28.8 99.8 2575.5605 2575.5616
7q 27.3 99.6 2683.6041 2683.6069
9 34.2 98.8 2210.3054 2211.8g
10 32.9 >99.9 2254.2952 2254.2970
11 30.4 >99.9 2180.2796 2180.2792
13 32.9 99.3 1970.0828 1970.0832
14 33.1 >99.9 1984.0985 1984.0994
16 30.8 99.9 2192.3966 2192.3962
18 27.3 >99.9 2105.3042 2105.3043
19 27.0 >99.9 2210.3620 2210.3630
20 27.6 >99.9 2195.3511 2195.3513
aHPLC retention time: column: Vydac 208TP104 (reverse-phase C8, 4.6
× 250 mm). Flow rate: 1.0 mL min−1. Eluent A: H2O + 0.1%
CF3COOH, eluent B: MeCN + 0.1% CF3COOH. Gradient from 20% to
90% B in 35 min. bAnalysis by an evaporative light scattering detector.
cMonoisotopic mass. dReconstructed monoisotopic mass. e Eluent A:
H2O/MeCN (85 : 15) + 0.1% CF3COOH, eluent B: MeCN + 0.1%
CF3COOH. Gradient from 10% to 100% B in 45 min.
f Eluent A: H2O/
MeCN (85 : 15) + 0.1% CF3COOH, eluent B: MeCN + 0.1%
CF3COOH. Gradient from 30% to 100% B in 35 min.
gMost abundant
mass observed for the adduct [M + H]+.†
Fig. 3 Selected dose–response curves for quantifying the inhibition of
Aβ40 secretion by tripartite structures with different membrane anchors.
Aβ40 concentrations in cell culture supernatants are expressed as percent
of the control condition C (1% DMSO). Compounds 6a and 6b were
tested at concentrations ranging from 10 pM to 100 nM in SH-SY5Y
APPwt cells. 6c and 6i were tested at concentrations from 1 nM to
10 μM; 6d was tested with alternating concentration ranges (once:
100 pM to 1 μM; twice: 1 nM to 10 μM); 6f was tested at concentrations
from 100 pM to 1 μM. The dose–response curves were generated by
pooling normalised data (means and SD) from three independent
experiments (ESI, Table S2†). It should be noted that the concentration
ranges were varied between experiments for some compounds. In cases
where error bars are shown, they represent data from at least two
independent experiments.
8218 | Org. Biomol. Chem., 2012, 10, 8216–8235 This journal is © The Royal Society of Chemistry 2012
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Chol) did not reach statistical significance. However, both were
significantly lower than each single log EC50 value obtained for
6c–6i (for pairwise comparison of different anchors, see ESI,
Table S1†). This result is explained by the different partitioning
of sterol and lipid alcohol anchors between raft and non-raft
phases. As dihydrocholesteryl anchors bind more efficiently to
the raft phase,25 the tripartite structures 6a and 6b should be
available in higher concentrations at the subcellular site of amy-
loidogenic APP cleavage. Within the series of tripartite structures
with lipid alcohol anchors, a chain length of 18 to 24 carbon
atoms provided the best result. Compounds 6e–h were equally
potent (Fig. 4), whereas the log EC50 of 6c (log EC50 = −6.752
± 0.266) with the shortest lipid chain (C14) was significantly
higher than all other log EC50 values in this series (p < 0.001;
ESI, Table S1†). Compared to compounds 6e–h, the potency
appeared to decrease for 6d (log EC50 = −7.609 ± 0.342) and 6i
(log EC50 = −7.631 ± 0.124) with chain lengths of 16 and 26
atoms, albeit statistical significance was not reached. It is
assumed that the observed influence of the chain length within
lipid alcohol anchors may reflect subtle differences in the distri-
bution between raft and non-raft domains.
Variations of the spacer module
According to the original tripartite structure concept,24 the
length of the spacer linking the pharmacophore to the membrane
anchor was expected to play a crucial role for the inhibitory
activity. The optimum spacer should position the pharmacophore
at a distance from the plasma membrane approximately matching
that of the BACE1 active site (or that of the β-secretase cleavage
site within APP) (Fig. 1). Theoretical spacer lengths of our tri-
partite inhibitors have been estimated assuming an all-anti-con-
formation for the chain. Therefore, these lengths correspond to a
maximal theoretical length irrespective of the actual confor-
mation of the spacer. In a previous study, tripartite structures
with theoretical spacer lengths ranging from 35 to 89 Å were
shown to efficiently reduce cellular Aβ production (compound
6a with an 89 Å spacer displayed the lowest EC50 value).
26 To
extend our previous work and to investigate the influence of
both, spacer length and chemical composition, we tested a series
of tripartite structures with theoretical spacer lengths ranging
from 26 to 96 Å. The subtle variations in length in this range
were implemented by different combinations of the spacer build-
ing blocks 4a–c, thus providing eleven tripartite structures: 6a,
7b, 7d, 7e, 7g–i, 7l, 7n, 7o and 7q (Table 1 and 3).
Spacers with different chemical entities were tested. Pre-
viously, different spacer lengths ranging from 35 to 123 Å were
assembled by amide coupling of the ω-aminooligoethylene
glycol carboxylic acids 4a and 4b. In compounds 7a, 7c, 7f, 7m
and 7p one-block oligoethylene glycol units have been used as
spacers. They derive from the ω-aminooligoethylene glycol car-
boxylic acids 4c–g containing 6, 8, 12, 16 and 24 oligoethylene
glycol units and thus have no amide bonds within the spacer
module. The phenylacetic acids 5a and 5b were used to construct
a further type of spacer and led to the tripartite structures 7j and
7k with more lipophilic aromatic moieties in the spacer module
(Fig. 2).
In order to get data which are comparable to the previous
ones, dihydrocholesterol was used as a lipid anchor and the pep-
tidic transition state inhibitor GL189 as a pharmacophore. The
tripartite structures 6a and 7a–q were shown to be highly active
(Table 3). Irrespective of the chemical composition of the spacer
and the theoretical length (ranging from 26–96 Å), 6a and 7a–q
exhibited EC50 values below 7 nM. This finding indicates that
within these limits the activities of our tripartite structures are
relatively independent of the structure of the spacer module.
As shown in Fig. 5, the log EC50 values of the tripartite struc-
tures 6a and 7a–q did not show a single minimum. The com-
pounds could be roughly divided into two groups with EC50
Table 2 Tripartite structures 6a–j with different membrane anchors
No. Sequencea EC50
b [nM]
6a 0.39
6b 0.74
6c 177.01
6d 24.60
6e 9.16
6f 6.82
6g 7.24
6h 7.66
6i 23.39
6j n.d.c
a Inhibitor: H-Glu-Val-Asn-Sta-Val-Ala-Glu-Phe; spacer: 4Gl-3Gl-4Gl-
3Gl-4Gl. bHalf maximal effect (EC50) of inhibition of Aβ40 secretion
from treated cells relative to control (1% DMSO). Log EC50 was
determined by non-linear regression from dose–response curves. The
value given is the delogarithmised mean value of three independent
experiments (ESI†). c n.d. = not determined, 6j was inactive at all
concentrations tested (up to 100 nM).
Fig. 4 Selected dose–response curves. Inhibition of Aβ40 secretion by
tripartite structures with different lipid alcohol anchors. Aβ40 concen-
trations in cell culture supernatants are expressed as percent of the
control condition C (1% DMSO). Compound 6e was tested with alterna-
ting concentration ranges (once: 1 nM–10 μM; twice: 100 pM–1 μM); com-
pounds 6f and 6h were tested at concentrations ranging from 100 pM to
1 μM in SH-SY5Y APPwt cells. Compound 6g was tested twice at nine
different concentrations from 100 pM–1 μM, while in the third exper-
iment, a reduced number of only six concentrations was tested, ranging
from 3 nM to 1 μM. Dose–response curves were generated by pooling
normalised data (means and SD) from three independent experiments.†
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 8216–8235 | 8219
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values below and above 1 nM, respectively. Interestingly, the
difference in potency does not seem to depend on the chemical
composition of the spacer. Among the structures with one-block
oligoethylene glycol spacers, the four compounds 7a, 7c, 7f and
7p exhibit EC50 values < 1 nM (7a: EC50 = 0.56 nM; log EC50 =
−9.248 ± 0.097; 7c: EC50 = 0.43 nM; log EC50 = −9.368 ±
0.228; 7f: EC50 = 0.37 nM; log EC50 = −9.436 ± 0.038; 7p:
EC50 = 0.79 nM; log EC50 = −9.104 ± 0.113), whereas the value
of compound 7m was much higher (EC50 = 6.18 nM, log EC50 =
−8.209 ± 0.216). Spacer modules containing phenylacetic acid
as in 7j and 7k did not affect the activity of the tripartite struc-
tures as compared to spacers consisting exclusively of oligoethy-
lene glycol units with theoretical spacer lengths from 48 Å to
58 Å (7j: EC50 = 0.45 nM; log EC50 = −9.343 ± 0.080; 7k: EC50
= 0.59 nM; log EC50 = −9.229 ± 0.282) (Table 3). For a statisti-
cal evaluation of the results, 6a was chosen as the reference. The
mean log EC50 values of each spacer variation were compared to
the mean log EC50 of 6a by one-way ANOVA followed by Dun-
nett’s multiple comparison post-test. The mean log EC50 values
of the tripartite structures 7d (log EC50 = −8.578 ± 0.327), 7e
(log EC50 = −8.954 ± 0.318), 7m (log EC50 = −8.209 ± 0.216),
7n (log EC50 = −8.702 ± 0.252) and 7q (logEC50 = −8.810 ±
0.055) were significantly different from that of 6a (log EC50 =
−9.406 ± 0.182).
Apparent minima of the EC50 values were observed for tripar-
tite structures with theoretical spacer lengths of 33 Å (7c: EC50
= 0.43 nM; log EC50 = −9.368 ± 0.228), 48 Å (7f: EC50 = 0.37
nM; log EC50 = −9.436 ± 0.038) and 89 Å (6a: EC50 = 0.39 nM;
log EC50 = −9.406 ± 0.182). However, it should be noted that
the subtle differences of activity of tripartite structures with EC50
values <1 nM did not reach statistical significance. In summary,
our results indicate that the relative potency of the tripartite struc-
tures with theoretical spacer lengths ranging from 26 to 96 Å did
neither solely depend on the number of amide groups nor on the
chemical composition of the spacers. Oligoethylene glycols can
form helical structures in water,28 and thus it does not seem
likely that the spacer molecules adopt a fully extended confor-
mation in a physiological environment. Interactions with the
aqueous medium and with cell membrane-related components
may influence the conformation of the spacer and thus affect the
potency of the tripartite structure.
Variation of the BACE1 inhibitor
Membrane anchoring considerably increases the efficacy of the
peptidic BACE1 inhibitor GL189 in cellular assays.24–26 In the
present study, the tripartite structure concept has been tested on
four literature-known BACE1 inhibitors: 8, 12, 15 and 17
(Fig. 6).29–32 The inhibitors were adapted for solid-phase peptide
synthesis to enable the attachment of a spacer and a raftophile.
Thus, the structures had to be modified by adding a carboxyl
group which served as a coupling partner for the N-terminus of
the spacer. The modified pharmacophores were synthesised fol-
lowing literature procedures.29–32 The additional carboxyl groups
either derive from modified protected starting materials or from
attachment of carboxyl group-bearing moieties at a later stage of
Table 3 Tripartite structures 6a and 7a–q with different spacers
No. Sequencea
Spacer
lengthb
[Å]
EC50
c
[nM]
7a 26 0.56
7b 31 0.53
7c 33 0.43
7d 35 2.64d
7e 47 1.11d
7f 48 0.37
7g 51 0.51
7h 53 0.52
7i 53 0.44
7j 53 0.45
7k 57 0.59
7l 58 0.81
7m 61 6.18
7n 63 1.99d
7o 77 0.67
6a 89 0.39d
7p 91 0.79
7q 96 1.55
a Inhibitor: H-Glu-Val-Asn-Sta-Val-Ala-Glu-Phe; raftophile: Asp
(ODhc)-NH2.
bMaximal theoretical spacer length, assuming an all-anti
conformation. cHalf maximal effect (EC50) of inhibition of Aβ40
secretion from treated cells relative to control (1% DMSO). The value
given is the delogarithmised mean log EC50 of three independent
experiments, except for 6a, which was tested in eight independent
experiments. All compounds were tested at concentrations from 10 pM to
100 nM, except for 7m, which was tested at alternating ranges (once:
10 pM–100 nM; twice: 100 pM–1 μM). Log EC50 was determined by non-
linear regression from dose–response curves (ESI, Table S2†). d EC50
values of compounds 6a, 7d, 7e and 7n were also reported in ref. 26.
Subtle differences are due to adjustments in the statistical analysis of the
data allowing direct comparison (ESI, Table S2†).
Fig. 5 Dependency of the log EC50 from the theoretical spacer length
for tripartite structures with oligoethylene glycol spacers. Compounds
7b, 7d, 7e, 7g–7l, 7n, 7o and 7q with assembled spacers are depicted as
blue dots. Compounds 7a, 7c, 7f, 7m and 7p with one-block spacers
without internal amide bonds are depicted as red squares. To assess the
statistical significance, the mean log EC50 values were compared to that
of compound 6a (green dot) by one way-ANOVA combined with Dun-
nett’s multiple comparison post-test. The mean log EC50 values of com-
pounds 7d, 7e, 7m, 7n and 7q were significantly different from that of
6a (**p < 0.01; ***p < 0.001) and higher than −9 (EC50 = 1 nM).
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the synthesis. Thus, the synthetic routes were kept similar to the
original procedures and the building blocks for the solid-phase
synthesis were obtained in a convergent manner.
The first small-molecule inhibitor examined was the lysine
derivative 8 (Elan Pharmaceuticals/Pharmacia & Upjohn;
Fig. 6).13,29 A Ki value of 5 nM was reported for that compound.
Tripartite structure 9 was obtained by coupling of the free car-
boxylic acid 8 to the spacer–membrane anchor module (-4Gl-
3Gl-4Gl-3Gl-4Gl-Asp(ODhc)-NH2). The tripartite structure 9
was reported to be an active inhibitor of BACE1 in cell-based
assays.26 This finding could not be reproduced and our present
study demonstrated that the previous result was caused by an
impurity.
In a previous structure–activity study, the isobutyl group at the
sulfonamide and the free carboxylic acid were found to be
crucial for the inhibitory effect of 8.29 Thus, the carboxylic acid
group of compound 8 should not be functionalised. As a
different coupling strategy might lead to active tripartite deriva-
tives of 8, we decided to connect the inhibitor and the spacer
either via modification of the p-toluenesulfonamide or by repla-
cement of the Fmoc-protecting group by a phenylacetic acid
derivative. Both analogues could still exhibit inhibitory activity
based on the structure–activity study.29 The building blocks 24
and 28 for the solid-phase peptide synthesis were prepared from
H-Lys(Cbz)-OtBu (21) (Scheme 2). For the synthesis of com-
pound 24 with the modified sulfonamide, amine 21 was reduc-
tively alkylated with isobutyraldehyde. The secondary amine
was converted into the sulfonamide 22 using benzyl 2-(4-(chloro-
sulfonyl)phenyl)acetate, which was prepared from 4-iodopheny-
lacetic acid via benzyl protection, copper-catalysed coupling
with thiobenzoic acid33 and subsequent oxidative chlorination
with trichloroisocyanuric acid.34 Deprotection of 22 by cleavage
of the benzyl ester and the carbamate followed by Fmoc-protec-
tion of the amine 23 afforded building block 24.
Fig. 6 BACE1 inhibitors 8, 12, 15, 17 and tripartite analogues 9–11, 13, 14, 16, 18–20. -4Gl-3Gl-4Gl-3Gl-4Gl-Asp(ODhc)-NH2.
EC50: inhibitor concentration at which inhibition of Aβ40 secretion from treated cells was half-maximal compared to the control condition (1%
DMSO). The value given is the delogarithmised mean log EC50 of three independent experiments. Log EC50 was determined by non-linear regression
from dose–response curves (ESI†).
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 8216–8235 | 8221
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Reductive amination of compound 21 and subsequent reaction
with 4-toluenesulfonyl chloride afforded the sulfonamide 25.29
Deprotection of the primary amine led to compound 26, which
on amidation with the acid 27 and cleavage of the benzyl ester
provided building block 28. Acid 27 is accessible by chemo-
selective protection of 4-hydroxyphenylacetic acid (34) as
benzyl ester,35 reaction with tert-butyl bromoacetate and
cleavage of the tert-butyl ester.
The free inhibitor 8 and the derived tripartite structures 9, 10
and 11 were all unable to inhibit the Aβ40-secretion from
SH-SY5YAPPwt cells at concentrations of up to 100 nM (8) and
1 μM (9, 10 and 11), respectively.
As the second small-molecule inhibitor we have chosen the
hydrazone 12 (The Genetics Company Inc., Switzerland;
Fig. 6).30 An IC50 value of 14.4 μM for an in vitro assay and
activity in a cell-based assay were reported.30,36 Since no infor-
mation on structure–activity relations was available, this inhibitor
was attached via the mono-substituted aromatic ring using a
benzoic or phenylacetic acid moiety (Scheme 3). The synthesis
of the building blocks 32 and 33 started from commercially
available 4-hydrazinobenzoic acid (30) and 4-hydrazinophenyl-
acetic acid (31), prepared by diazotation and reduction of
4-aminophenylacetic acid.37
Acid-catalysed condensation of ketone 29 with the hydrazines
30 and 31 provided the building blocks 32 and 33 with no need
for protecting group operations at the carboxylic acids.38 The tri-
partite structures 13 and 14, as well as the inhibitors 32 and 33
were unable to reduce the Aβ40-secretion from SH-SY5Y
APPwt cells at concentrations of up to 100 nM (Fig. 6).
The third non-peptidic small-molecule inhibitor of BACE1
investigated in our present study was the 2-amino-3,4-dihydro-
quinazoline 15 (Johnson & Johnson; Fig. 6).31 An X-ray analysis
of a structurally related 2-amino-3,4-dihydroquinazoline bound
to the active site of BACE1 showed that the primary amine inter-
acts with the catalytic aspartates of BACE1.31 A Ki value of 30
nM was found for rac-15, which was also active in a cell-based
assay. Attachment of this inhibitor to the tripartite structure was
achieved by substitution of the phenoxy group at the 6-position
of the 3,4-dihydroquinazoline 15 by a 4-hydroxyphenylacetic
acid. The primary amine and the cyclohexyl moieties are impor-
tant for the activity of 15 because they interact with the catalyti-
cally active aspartates or the S1 and S1′ pockets of BACE1,
respectively. Therefore, these structural units were left
untouched. Furthermore, the modified substituent at the 2-
amino-3,4-dihydroquinazoline could easily be introduced at the
beginning of the synthesis, keeping the remaining steps similar
to the known procedure (Scheme 4).31 4-Hydroxyphenylacetic
acid (34) was converted to the tert-butyl ester 35 using an excess
of tert-butyl acetoacetate.39 Nucleophilic aromatic substitution
by reaction of 5-fluoro-2-nitrobenzaldehyde with the phenol 35
provided the diaryl ether 36. Subsequent reductive amination
with amine 37 afforded compound 38.31 Reduction of 38 to the
aniline 39 followed by cyclisation using cyanogen bromide pro-
vided the 2-amino-3,4-dihydroquinazoline 40. Cleavage of the
tert-butyl ester led to the phenylacetic acid 41.40
The tripartite structure 16 turned out to be a potent inhibitor
of cellular Aβ release from SH-SY5YAPPwt cells. The EC50 of
14.8 nM (log EC50 = −7.831 ± 0.057) for 16 as compared to
5.4 μM (log EC50 = −5.266 ± 0.060) for the pharmacophore 41
indicated a substantial improvement of potency (Fig. 7). A sig-
nificant statistical difference for the mean log EC50 values of 16
and 41 was revealed by Student’s t-test (p < 0.0001). This result
showed that membrane targeting of a non-peptidic compound,
Scheme 2 Synthesis of the building blocks 24 and 28. Reagents and
conditions: (a) 1.14 equiv. isobutyraldehyde, 0.66 equiv. EtN(i-Pr)2,
1.14 equiv. NaBH3CN, 2.4 equiv. AcOH, MeOH, rt, 2 h, 92%; (b) 1.0
equiv. benzyl 2-(4-(chlorosulfonyl)phenyl)acetate, 1.0 equiv. EtN(i-Pr)2,
CH2Cl2, rt, 3 d, 63%; (c) cat. 10% Pd/C, H2 (1 atm), EtOAc, rt, 23 h,
95%; (d) 1.5 equiv. N-(FmocO)succinimide, MeCN, THF, 1 M K2CO3 in
H2O (1 : 1 : 1), rt, 17 h, 51%; (e) 1.0 equiv. TosCl, 1.5 equiv. EtN(i-Pr)2,
CH2Cl2, rt, 5 d, 88%; (f ) cat. 10% Pd/C, H2 (1 atm), EtOAc, rt, 24 h,
99%; (g) 1.0 equiv. 26, 1.5 equiv. 27, 1.5 equiv. EDC·HCl, cat. DMAP,
CH2Cl2, rt, 5 d, 56% (h) cat. 10% Pd/C, H2 (1 atm), EtOAc, rt, 2 h,
100%.
Scheme 3 Synthesis of the building blocks 32 and 33. Reagents and
conditions: 1.0 equiv. 30 or 31, 1.0 equiv. 29, 0.85 equiv. AcOH, EtOH,
78 °C, 2.5 h, 66% for 32, 51% for 33.
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which is only weakly active in a cellular assay, leads to a signifi-
cant increase of the inhibitory activity.
As the fourth small-molecule BACE1 inhibitor we tested the
spiropiperidine iminohydantoin 17 which was identified by
high-throughput screening (Merck; Fig. 6).32 An IC50 value of
2.8 μM on the isolated enzyme and an activity in a cellular assay
at 8.2 μM have been reported.32 The cyclohexyl and fluorophenyl
rings of 17 were found to be essential for high potency in vitro
and good activity in the cell-based assay, respectively. Therefore,
attachment to the spacer was achieved by modification of the
substituent at the piperidine nitrogen. The spiropiperidine 42 is
readily available via an Ugi reaction (Scheme 5).32 In a first
attempt the piperidine nitrogen of 42 was directly acylated with
Fmoc-Glu-OtBu (43). Subsequent acidic cleavage of the tert-
butyl ester afforded building block 44. For the two pharmaco-
phores 50 and 51, attachment to the spacer was projected by sub-
stitution of the 4-acetamido group of 17 with a glutamic or
glutaric acid linkage, respectively. Thus, the structure of the
pharmacophores was kept similar to the one reported in the lit-
erature. Protection of 4-nitrobenzyl alcohol by reaction with tert-
butylchlorodimethylsilane, reduction to the aniline,41 amidation
with either Fmoc-Glu-OtBu (43) or mono-tert-butyl glutarate,42
removal of the silyl protecting group and oxidation with manga-
nese dioxide43,44 afforded the benzaldehydes 45 and 46.
Reductive amination of the spiropiperidine 42 with the benzal-
dehydes 45 and 46 and subsequent cleavage of the tert-butyl
ester led to compound 49 and the pharmacophore 50. Cleavage
of the Fmoc group in 49 provided the glutamic acid-derived
pharmacophore 51.
The tripartite structures 19 and 20 exhibited potent inhibition
of Aβ40-secretion in a cellular assay with EC50 values of 50.1 nM
(log EC50 = −7.300 ± 0.163) and 9.7 nM (log EC50 = −8.014
± 0.048) (Fig. 6), whereas the reference substances 17, 50 and
51 showed considerably higher EC50 values of 0.863 μM (log
EC50 = −6.064 ± 0.178), 17.5 μM (log EC50 = −4.758 ± 0.212)
and 4.3 μM (log EC50 = −5.368 ± 0.150), respectively
(Scheme 5; ESI, Table S2†). The tripartite structure 18 failed to
inhibit BACE1 at concentrations up to 10 μM. Pairwise compari-
son of the log EC50 values for the tripartite structures 19 and 20
and the free pharmacophores 17, 50 and 51 by one-way ANOVA
and Tukey’s post-test showed that all five differed significantly
from each other (ESI, Fig. S1 and Table S3†). In contrast to 18,
the tripartite structures 19 and 20, which resemble structure 17
Scheme 4 Synthesis of building block 41. Reagents and conditions:
(a) 6.4 equiv. tert-butyl acetoacetate, 0.08 equiv. conc. H2SO4, closed
vessel, rt, 45 h, 41%; (b) 1.0 equiv. 5-fluoro-2-nitrobenzaldehyde, 1.2
equiv. K2CO3, DMF, 120 °C, 45 min, 63%; (c) 1.0 equiv. 36, 1.0 equiv.
37, 1.1 equiv. NaBH3CN, 1.0 equiv. AcOH, CH2Cl2, rt, 17 h, 83%; (d)
cat. 10% Pd/C, H2 (1 atm), MeOH, rt, 2 h, 94%; (e) 1.5 equiv. BrCN,
EtOH, 78 °C, 17 h, 84%; (f ) 8.2 wt-equiv. silica gel, toluene, 111 °C,
3.5 h, 99%.
Fig. 7 (A) Dose–response curves: inhibition of Aβ40 secretion by tri-
partite structure 16 (red dots) and pharmacophore 41 (black squares).
Aβ40 concentrations in cell culture supernatants are expressed as percent
of the control condition C (1% DMSO). The curves were generated by
non-linear regression on pooled normalised data from three independent
experiments. Compound 16 was tested in alternating concentration
ranges in SH-SY5Y APPwt cells (once: 30 pM–100 nM, 1 μM; twice:
300 pM–3 μM). Compound 41 was tested in two experiments at nine different
concentrations ranging from 10 nM to 100 μM and for confirmation, in a
third experiment at a reduced number of concentrations (10 nM, 100 nM,
1 μM, 10 μM, 100 μM). (B) Log EC50 values of tripartite structure 16 and
pharmacophore 41 from three independent experiments were compared
by an unpaired, two-tailed t-test. Mean log EC50 values were signifi-
cantly different (***p < 0.0001). The lines and error bars represent
means and standard deviations from three independent experiments.
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 8216–8235 | 8223
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more closely, were highly active. The potency of 20, the most
active tripartite structure within this series, exceeded that of
inhibitor 17 by almost two orders of magnitude. This outcome
emphasises that the potency of intrinsically cell-permeable
BACE1 inhibitors can be enhanced considerably by membrane
anchoring. The tripartite structure 20 is significantly more active
than 19, which differs from the former only by the presence of
an amino group in the linkage to the pharmacophore. Obviously,
decreased polarity in the region of the hydrophobic S3 binding
pocket results in increased activity.
Conclusions
The present results provide strong evidence for our tripartite
structure concept.24 We have demonstrated that the cellular
activity of small-molecule BACE1 inhibitors can be significantly
increased by membrane targeting via a spacer with a raftophilic
membrane anchor. A careful selection of the coupling strategy is
crucial to avoid alteration of essential pharmacophoric groups of
the inhibitor which may lead to a loss of inhibitory activity. The
tripartite structure concept leads to an enrichment of the mem-
brane-bound inhibitor in the lipid rafts which may reduce
unwanted off-target side effects caused by the free BACE1
inhibitor. The ability of the membrane anchor to bind to lipid
rafts strongly depends on its structure. This raftophilicity deter-
mines the concentration of the tripartite structure at the site of
APP cleavage and therefore the potency of our compounds. Our
observations indicate that a variation of the theoretical linker
length from 26 to 96 Å has only a small impact on the inhibitory
activity of the tripartite structure. This observation is tentatively
explained by a spacer conformation which is not fully elongated
in an aqueous environment. It is a further advantage of our
concept that tripartite structures are relatively tolerant to struc-
tural changes in the spacer.
Experimental
General
The spacer building blocks 4a and 4b, and Fmoc-statine were
purchased from Polypeptide, France. The spacer building blocks
4c–g were purchased from Iris Biotech, Germany. The other
amino acids and activation agents were bought from Novabio-
chem/Merck. All reactions were carried out using dry solvents in
oven-dried glassware under an argon atmosphere. Solvents were
dried using a solvent purification system (MBraun-SPS). Other
chemicals were used as received from commercial sources. Flash
chromatography was carried out using silica gel from Acros
Organics (0.035–0.070 mm) and a Sepacore system (Büchi). The
tripartite structures were assembled by automated solid-phase
peptide synthesis on an ABI 433A peptide synthesiser with a
UV detector (Fmoc-strategy, PAL-PEG-PS resin, HATU or
HBTU activation). ATR FT-IR spectra were recorded on a
Thermo Nicolet Avatar 360. NMR spectra were recorded on a
Bruker Avance II 300, on a Bruker DRX 500 and an Avance III
600; δ in ppm with the non-deuterated solvent as an internal
standard,45 J in Hz. Mass spectra were measured on a Bruker
Esquire LC Electrospray MS. The most abundant mass is given
as theoretical mass. HRMS was measured on an LTQ ORBI-
TRAP XL instrument (ThermoScientific) with a resolution of
60 000 and a mass accuracy within 3 ppm. Analytical HPLC
was carried out on an Agilent Model 1100 with G1315B
UV-DAD (detection at 215, 260 and 560 nm), G1321A fluor-
escence and an evaporative light scattering detector (ELS 1000,
Polymer Laboratories). Column: Vydac 208TP104 (reverse-
phase C8, 4.6 × 250 mm). Flow rate: 1.0 mL min
−1. Eluent A:
H2O + 0.1% CF3COOH, eluent B: MeCN + 0.1% CF3COOH.
Gradient from 20% to 90% B in 35 min. Preparative HPLC was
carried out using a Varian PrepStar system, with a Varian ProStar
Model 320 UV and an evaporative light scattering detector (ELS
1000, Polymer Laboratories) connected via a Sunchrom Quick-
Split splitter. Column: Vydac 208TP1050 (reverse-phase C8, 50 ×
250 mm). Flow rate: 55 mL min−1. Eluent A: H2O + 0.1%
CF3COOH, eluent B: MeCN + 0.1% CF3COOH. Gradient stated
for the individual compounds.
Fmoc-Asp(ODhc)-OH (3a). For synthesis and spectroscopic
data, see ref. 26.
Fmoc-Asp(OChol)-OH (3b). Cholesterol (1.29 g, 3.33 mmol)
and a catalytic amount of DMAP were added to a solution of
Fmoc-Asp-OtBu (1) (1.99 g, 4.83 mmol) and EDC·HCl
(0.938 g, 4.89 mmol) in CH2Cl2 (60 mL). After stirring for 52 h
Scheme 5 Synthesis of the building blocks 44, 49 and 50. Reagents
and conditions: (a) 1.9 equiv. Fmoc-Glu-OtBu (43), 1.9 equiv. HATU,
4.3 equiv. EtN(i-Pr)2, CH2Cl2, rt, 18 h; (b) CF3COOH, CH2Cl2 (1 : 1),
rt, 90 min, 57% (two steps); (c) 1.4 equiv. 45 or 2.3 equiv. 46, 3.0 equiv.
NaBH(OAc)3, 1.5 equiv. EtN(i-Pr)2, 1,2-C2H4Cl2, rt, 18–19 h, 70% for
47, 73% for 48; (d) CF3COOH, CH2Cl2 (1 : 1), rt, 90 min, 78%; (e) 10.0
wt-equiv. silica gel, toluene, 111 °C, 6 h, 86%; (f ) piperidine, DMF
(1 : 5), rt, 3.5 h, 75%.
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at room temperature, the mixture was partitioned between 2%
aqueous citric acid and CH2Cl2, washed with 2% citric acid,
H2O and brine. The organic layer was dried over Na2SO4 and
evaporated to yield a colourless solid, which was dissolved in
CH2Cl2 (30 mL). CF3COOH (30 mL) was added at 0 °C, the
mixture was stirred at room temperature for 90 min, diluted with
CH2Cl2 and washed four times with water and once with brine.
After drying over Na2SO4 and removal of the solvent, the
residue was purified by flash chromatography (SiO2; pentane/
ethyl acetate [2 : 1] + 0.5% AcOH), affording 3b as a colourless
solid, yield: 1.46 g (61%), m.p. 157–158 °C. IR (ATR): ν =
2932, 2867, 2850, 1725, 1703, 1653, 1558, 1515, 1447, 1376,
1330, 1273, 1218, 1084, 1029, 1008, 957, 849, 801, 757,
735 cm−1. 1H NMR (500 MHz, CDCl3): δ = 0.67 (s, 3 H),
0.85–1.62 (m, 33 H), 1.79–1.87 (m, 3 H), 1.94–2.02 (m, 2 H),
2.32 (d, J = 7.9 Hz, 2 H), 2.86 (dd, J = 17.3, 4.7 Hz, 1 H), 3.06
(dd, J = 17.6, 4.1 Hz, 1 H), 4.24 (t, J = 7.3 Hz, 1 H), 4.31–4.39
(m, 1 H), 4.40–4.47 (m, 1 H), 4.57–4.72 (m, 2 H), 5.37 (d, J =
3.8 Hz, 1 H), 5.87 (d, J = 8.2 Hz, 1 H), 7.31 (t, J = 7.6 Hz, 2 H),
7.40 (t, J = 7.6 Hz, 2 H), 7.58–7.61 (m, 2 H), 7.76 (d, J =
7.6 Hz, 2 H). 13C NMR and DEPT (125 MHz, CDCl3): δ =
11.99 (CH3), 18.86 (CH3), 19.42 (CH3), 21.16 (CH2), 22.71
(CH3), 22.97 (CH3), 23.99 (CH2), 24.41 (CH2), 27.79 (CH2),
28.16 (CH), 28.37 (CH2), 31.95 (CH), 32.02 (CH2), 35.94 (CH),
36.32 (CH2), 36.69 (C), 36.88 (CH2), 37.03 (CH2), 38.08 (CH2),
39.65 (CH2), 39.83 (CH2), 42.44 (C), 47.20 (CH), 49.10 (CH),
50.34 (CH), 56.28 (CH), 56.80 (CH), 67.55 (CH2), 75.57 (CH),
120.15 (2 CH), 123.13 (CH), 125.25 (CH), 125.29 (CH), 127.24
(2 CH), 127.90 (2 CH), 139.40 (C), 141.44 (2 C), 143.78 (C),
143.92 (C), 156.24 (CvO), 170.80 (CvO), 175.67 (CvO).
ESI-MS: m/z = 724.5 [M + H]+, 741.7 [M + NH4]
+.
Fmoc-Asp(O-C14H29)-OH (3c). A solution of Fmoc-Asp-
OtBu (1) (5.56 g, 13.5 mmol), MSNT (4.00 g, 13.5 mmol) and
MeIm (1.11 g, 13.5 mmol) in CH2Cl2 (60 mL) was stirred for
10 min and myristyl alcohol (2.63 g, 12.3 mmol) was added sub-
sequently. After stirring for 4 h at room temperature, the mixture
was partitioned between 2% aqueous citric acid and CH2Cl2,
washed with 2% citric acid, H2O and brine. After drying over
Na2SO4 and removal of the solvent, the residue was purified by
flash chromatography (SiO2; petroleum ether/diethyl ether, 2 : 1),
affording the protected ester as a colourless solid, yield: 5.56 g
(76%). This product (5.00 g, 8.23 mmol) was dissolved in
CH2Cl2 (15 mL). CF3COOH (10 mL) was added at 0 °C, the
mixture stirred at room temperature for 90 min, diluted with
CH2Cl2 and washed four times with water and once with brine.
After drying over Na2SO4 and removal of the solvent, the
residue was purified by flash chromatography (SiO2; petroleum
ether/diethyl ether [2 : 1] + 0.5% AcOH), affording 3c as a col-
ourless solid, yield: 3.99 g (88%). IR (ATR): ν = 3355, 3247,
2920, 2851, 2057, 1724, 1652, 1543, 1470, 1457, 1404, 1372,
1280, 1237, 1184, 1083, 995, 832, 809, 770, 735 cm−1. 1H
NMR (500 MHz, CDCl3): δ = 0.88 (t, J = 6.9 Hz, 3 H),
1.22–1.31 (m, 22 H), 1.59–1.65 (m, 2 H), 2.89 (d, J = 15.5 Hz,
1 H), 3.10 (d, J = 15.5 Hz, 1 H), 4.12 (t, J = 6.4 Hz, 2 H), 4.24
(t, J = 6.6 Hz, 1 H), 4.33–4.37 (m, 1 H), 4.42–4.46 (m, 1 H),
4.70 (br s, 1 H), 5.87 (br d, J = 7.7 Hz, 1 H), 7.31 (t, J = 7.3 Hz,
2 H), 7.40 (t, J = 7.4 Hz, 2 H), 7.57–7.61 (m, 2 H), 7.76 (d, J =
7.5 Hz, 2 H). 13C NMR and DEPT (125 MHz, CDCl3): δ =
14.28 (CH3), 22.84 (CH2), 26.00 (CH2), 28.61 (CH2), 29.37
(CH2), 29.51 (CH2), 29.67 (CH2), 29.73 (CH2), 29.80 (3 CH2),
29.84 (CH2), 32.06 (CH2), 36.54 (CH2), 47.20 (CH), 50.31
(CH), 65.81 (CH2), 67.60 (CH2), 120.14 (2 CH), 125.26 (CH),
125.30 (CH), 127.23 (2 CH), 127.88 (2 CH), 141.43 (2 C),
143.76 (C), 143.89 (C), 156.26 (CvO), 171.43 (CvO), 175.69
(CvO). ESI-MS: m/z = 552.3 [M + H]+, 569.3 [M + NH4]
+.
Fmoc-Asp(O-C16H33)-OH (3d). A solution of Fmoc-Asp-
OtBu (1) (1.00 g, 2.43 mmol), MSNT (0.721 g, 2.43 mmol) and
MeIm (0.204 g, 2.43 mmol) in CH2Cl2 (60 mL) was stirred for
10 min and palmityl alcohol (0.651 g, 2.68 mmol) was added
subsequently. After stirring for 4 h at room temperature, the
mixture was partitioned between 2% aqueous citric acid and
CH2Cl2, washed with 2% citric acid, H2O and brine. After
drying over Na2SO4 and removal of the solvent, the residue was
purified by flash chromatography (SiO2; petroleum ether/diethyl
ether, 2 : 1), affording the protected ester as a colourless solid,
yield: 1.27 g (75%). This product (0.904 g, 1.42 mmol) was dis-
solved in CH2Cl2 (15 mL). CF3COOH (10 mL) was added at
0 °C, the mixture stirred at room temperature for 90 min, diluted
with CH2Cl2 and washed four times with water and once with
brine. After drying over Na2SO4 and removal of the solvent, the
residue was purified by flash chromatography (SiO2; petroleum
ether/diethyl ether [2 : 1] + 0.5% AcOH), affording 3d as a col-
ourless solid, yield: 0.702 g (85%). IR (ATR): ν = 3375, 3065,
2917, 2848, 2057, 1757, 1678, 1535, 1450, 1377, 1358, 1254,
1193, 1166, 1090, 1043, 988, 861, 736 cm−1. 1H NMR
(500 MHz, CDCl3): δ = 0.88 (t, J = 6.9 Hz, 3 H), 1.20–1.35 (m,
26 H), 1.59–1.65 (m, 2 H), 2.89 (dd, J = 17.4, 4.6 Hz, 1 H),
3.10 (dd, J = 17.4, 4.1 Hz, 1 H), 4.12 (t, J = 6.7 Hz, 2 H), 4.24
(t, J = 7.2 Hz, 1 H), 4.33–4.37 (m, 1 H), 4.41–4.46 (m, 1 H),
4.66–4.72 (m, 1 H), 5.84 (br d, J = 8.5 Hz, 1 H), 7.31 (t, J =
7.3 Hz, 2 H), 7.40 (t, J = 7.4 Hz, 2 H), 7.56–7.61 (m, 2 H), 7.75
(d, J = 7.5 Hz, 2 H). 13C NMR and DEPT (125 MHz, CDCl3): δ
= 14.29 (CH3), 22.85 (CH2), 26.00 (CH2), 28.61 (CH2), 29.39
(CH2), 29.52 (CH2), 29.67 (CH2), 29.74 (CH2), 29.81 (CH2),
29.84 (5 CH2), 32.08 (CH2), 36.52 (CH2), 47.21 (CH), 50.28
(CH), 65.82 (CH2), 67.58 (CH2), 120.15 (2 CH), 125.25 (CH),
125.28 (CH), 127.24 (2 CH), 127.90 (2 CH), 141.44 (2 C),
143.76 (C), 143.90 (C), 156.25 (CvO), 171.46 (CvO), 175.33
(CvO). ESI-MS: m/z = 580.3 [M + H]+, 597.3 [M + NH4]
+.
Fmoc-Asp(O-C18H37)-OH (3e). A solution of Fmoc-Asp-
OtBu (1) (0.503 g, 1.22 mmol), MSNT (0.363 g, 1.21 mmol)
and MeIm (99 mg, 1.22 mmol) in CH2Cl2 (20 mL) was stirred
for 10 min and stearyl alcohol (301 mg, 1.11 mmol) was added
subsequently. After stirring for 14 h at room temperature, the
mixture was partitioned between 2% aqueous citric acid and
CH2Cl2, washed with 2% citric acid, H2O and brine. The
organic layer was dried over Na2SO4 and evaporated to yield a
colourless viscous oil, which was dissolved in CH2Cl2 (5 mL).
After addition of CF3COOH (6.25 mL) at 0 °C, the mixture was
stirred at room temperature for 90 min, diluted with CH2Cl2 and
washed four times with water and once with brine. After drying
over Na2SO4 and removal of the solvent, the residue was
purified by flash chromatography (SiO2; petroleum ether/ethyl
acetate [2 : 1] + 0.5% AcOH), affording 3e as a colourless solid,
yield: 0.568 g (76%), m.p. 97–99 °C. IR (ATR): ν = 3377, 3064,
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 8216–8235 | 8225
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2916, 2849, 1757, 1734, 1693, 1678, 1533, 1472, 1450, 1377,
1358, 1322, 1253, 1195, 1166, 1089, 1043, 990, 860, 736 cm−1.
1H NMR (500 MHz, CDCl3): δ = 0.88 (t, J = 6.9 Hz, 3 H),
1.17–1.34 (m, 30 H), 1.57–1.69 (m, 2 H), 2.89 (dd, J = 17.4,
4.5 Hz, 1 H), 3.09 (dd, J = 17.3, 3.9 Hz, 1 H), 4.12 (t, J = 6.7
Hz, 2 H), 4.23 (t, J = 7.2 Hz, 1 H), 4.32–4.40 (m, 1 H),
4.39–4.49 (m, 1 H), 4.64–4.75 (m, 1 H), 5.86 (d, J = 8.3 Hz, 1
H), 7.31 (t, J = 7.4 Hz, 2 H), 7.40 (t, J = 7.4 Hz, 2 H), 7.59 (d,
J = 5.8 Hz, 2 H), 7.76 (d, J = 7.5 Hz, 2 H). 13C NMR and DEPT
(125 MHz, CDCl3): δ = 14.28 (CH3), 22.84 (CH2), 26.00 (CH2),
28.60 (CH2), 29.39 (CH2), 29.51 (CH2), 29.67 (CH2), 29.74
(CH2), 29.81 (CH2), 29.85 (7 CH2), 32.07 (CH2), 36.55 (CH2),
47.21 (CH), 50.30 (CH), 65.79 (CH2), 67.55 (CH2), 120.14
(2 CH), 125.25 (CH), 125.29 (CH), 127.24 (2 CH), 127.90 (2
CH), 141.44 (2 C), 143.78 (C), 143.90 (C), 156.26 (CvO),
171.51 (CvO), 174.46 (CvO). ESI-MS: m/z = 608.3 [M + H]+,
625.4 [M + NH4]
+.
Fmoc-Asp(O-C20H41)-OH (3f). A solution of Fmoc-Asp-
OtBu (1) (1.51 g, 3.68 mmol), MSNT (1.09 g, 3.67 mmol) and
MeIm (0.311 g, 3.67 mmol) in CH2Cl2 (60 mL) was stirred for
10 min and arachidyl alcohol (1.00 g, 3.36 mmol) was added
subsequently. After stirring for 17 h at room temperature, the
mixture was partitioned between 2% aqueous citric acid and
CH2Cl2, washed with 2% citric acid, H2O and brine. The
organic layer was dried over Na2SO4 and evaporated to yield a
colourless viscous oil, which was dissolved in CH2Cl2 (60 mL).
CF3COOH (60 mL) was added at 0 °C, the mixture stirred at
room temperature for 90 min, diluted with CH2Cl2 and washed
four times with water and once with brine. After drying over
Na2SO4 and removal of the solvent, the residue was purified by
flash chromatography (SiO2; petroleum ether/ethyl acetate [2 : 1]
+ 0.5% AcOH), affording 3f as a colourless solid, yield: 1.45 g
(68%), m.p. 97–99 °C. IR (ATR): ν = 3387, 3066, 2916, 2849,
1755, 1734, 1713, 1693, 1512, 1472, 1450, 1378, 1359, 1320,
1252, 1193, 1166, 1090, 1042, 992, 860, 775, 755, 736,
720 cm−1. 1H NMR (500 MHz, CDCl3): δ = 0.88 (t, J = 6.9 Hz,
3 H), 1.19–1.35 (m, 34 H), 1.60–1.66 (m, 2 H), 2.89 (dd, J =
17.4, 4.7 Hz, 1 H), 3.09 (dd, J = 17.4, 4.2 Hz, 1 H), 4.12 (t, J =
6.7 Hz, 2 H), 4.24 (t, J = 7.1 Hz, 1 H), 4.36 (s, 1 H), 4.41–4.48
(m, 1 H), 4.67–4.75 (m, 1 H), 5.85 (d, J = 8.4 Hz, 1 H), 7.31 (t,
J = 7.2 Hz, 2 H), 7.40 (t, J = 7.4 Hz, 2 H), 7.59 (d, J = 5.4 Hz,
2 H), 7.76 (d, J = 7.5 Hz, 2 H). 13C NMR and DEPT (125 MHz,
CDCl3): δ = 14.28 (CH3), 22.84 (CH2), 25.99 (CH2), 28.60
(CH2), 29.38 (CH2), 29.51 (CH2), 29.67 (CH2), 29.74 (CH2),
29.81 (CH2), 29.85 (9 CH2), 32.07 (CH2), 36.52 (CH2), 47.21
(CH), 50.25 (CH), 65.82 (CH2), 67.57 (CH2), 120.15 (2 CH),
125.24 (CH), 125.28 (CH), 127.24 (2 CH), 127.90 (2 CH),
141.44 (2 C), 143.77 (C), 143.89 (C), 156.24 (CvO), 171.49
(CvO), 174.87 (CvO). ESI-MS: m/z = 636.6 [M + H]+, 653.5
[M + NH4]
+.
Fmoc-Asp(O-C22H45)-OH (3g). A solution of Fmoc-Asp-
OtBu (1) (1.68 g, 4.09 mmol), MSNT (1.21 g, 4.08 mmol) and
MeIm (0.335 g, 4.09 mmol) in CH2Cl2 (60 mL) was stirred for
10 min and behenyl alcohol (1.22 g, 3.72 mmol) was added sub-
sequently. After stirring for 24 h at room temperature, the
mixture was partitioned between 2% aqueous citric acid and
CH2Cl2, washed with 2% citric acid, H2O and brine. The
organic layer was dried over Na2SO4 and evaporated to yield a
colourless solid, which was dissolved in CH2Cl2 (60 mL).
CF3COOH (60 mL) was added at 0 °C, the mixture stirred at
room temperature for 90 min, diluted with CH2Cl2 and washed
four times with water and once with brine. After drying over
Na2SO4 and removal of the solvent, the residue was purified by
flash chromatography (SiO2; petroleum ether/ethyl acetate [2 : 1]
+ 0.5% AcOH), affording 3g as a colourless solid, yield: 2.28 g
(92%), m.p. 98–100 °C. IR (ATR): ν = 3387, 3066, 2916, 2849,
1755, 1732, 1712, 1539, 1515, 1472, 1450, 1380, 1359, 1320,
1252, 1206, 1091, 1041, 989, 965, 935, 860, 775, 756, 737,
718 cm−1. 1H NMR (500 MHz, CDCl3): δ = 0.88 (t, J = 6.8 Hz,
3 H), 1.19–1.30 (m, 38 H), 1.57–1.68 (m, 2 H), 2.89 (dd, J =
17.4, 4.5 Hz, 1 H), 3.09 (dd, J = 17.4, 4.2 Hz, 1 H), 4.11 (t, J =
6.7 Hz, 2 H), 4.23 (t, J = 7.2 Hz, 1 H), 4.31–4.48 (m, 2 H),
4.63–4.72 (m, 1 H), 5.89 (d, J = 8.5 Hz, 1 H), 7.31 (t, J =
7.3 Hz, 2 H), 7.40 (t, J = 7.4 Hz, 2 H), 7.55–7.63 (m, 2 H), 7.76
(d, J = 7.5 Hz, 2 H). 13C NMR and DEPT (125 MHz, CDCl3): δ
= 14.28 (CH3), 22.84 (CH2), 26.00 (CH2), 28.60 (CH2), 29.39
(CH2), 29.51 (CH2), 29.68 (CH2), 29.75 (CH2), 29.81 (CH2),
29.86 (11 CH2), 32.07 (CH2), 36.52 (CH2), 47.20 (CH), 50.30
(CH), 65.79 (CH2), 67.57 (CH2), 120.14 (2 CH), 125.25 (CH),
125.29 (CH), 127.24 (2 CH), 127.89 (2 CH), 141.43 (2 C),
143.77 (C), 143.90 (C), 156.26 (CvO), 171.42 (CvO), 175.61
(CvO). ESI-MS: m/z = 664.4 [M + H]+, 681.5 [M + NH4]
+.
Fmoc-Asp(O-C24H49)-OH (3h). A solution of Fmoc-Asp-
OtBu (1) (0.127 g, 0.314 mmol), MSNT (91.8 mg, 0.31 mmol)
and MeIm (25.3 mg, 0.312 mmol) in CH2Cl2 (25 mL) was
stirred for 10 min and lignoceryl alcohol (0.100 g, 0.284 mmol)
was added subsequently. After stirring for 24 h at room tempera-
ture, the mixture was partitioned between 2% aqueous citric acid
and CH2Cl2, washed with 2% citric acid, H2O and brine. The
organic layer was dried over Na2SO4 and evaporated to yield a
colourless solid, which was dissolved in CH2Cl2 (5 mL).
CF3COOH (6.25 mL) was added at 0 °C, the mixture stirred at
room temperature for 90 min, diluted with CH2Cl2 and washed
four times with water and once with brine. After drying over
Na2SO4 and removal of the solvent, the residue was purified by
flash chromatography (SiO2; petroleum ether/ethyl acetate [2 : 1]
+ 0.5% AcOH), affording 3h as a colourless solid, yield: 0.137 g
(70%), m.p. 97–99 °C. IR (ATR): ν = 3315, 2916, 2848, 1770,
1735, 1690, 1652, 1636, 1535, 1464, 1449, 1412, 1398, 1369,
1340, 1281, 1231, 1176, 1105, 1087, 1049, 1015, 921, 779, 756,
735, 637 cm−1. 1H NMR (500 MHz, CDCl3): δ = 0.88 (t, J =
7.0 Hz, 3 H), 1.23–1.36 (m, 42 H), 1.59–1.69 (m, 2 H), 2.88
(dd, J = 17.4, 4.7 Hz, 1 H), 3.08 (dd, J = 17.4, 4.3 Hz, 1 H),
4.12 (t, J = 6.7 Hz, 2 H), 4.23 (t, J = 7.1 Hz, 1 H), 4.34–4.40
(m, 1 H), 4.42–4.49 (m, 1 H), 4.69–4.72 (m, 1 H), 5.86 (d, J =
8.5 Hz, 1 H), 7.31 (t, J = 7.3 Hz, 2 H), 7.40 (t, J = 7.5 Hz, 2 H),
7.60 (d, J = 5.2 Hz, 2 H), 7.76 (d, J = 7.5 Hz, 2 H). 13C NMR
and DEPT (125 MHz, CDCl3): δ = 14.28 (CH3), 22.84 (CH2),
26.00 (CH2), 28.61 (CH2), 29.39 (CH2), 29.51 (CH2), 29.68
(CH2), 29.75 (CH2), 29.81 (CH2), 29.86 (13 CH2), 32.07 (CH2),
36.52 (CH2), 47.21 (CH), 50.36 (CH), 65.82 (CH2), 67.57
(CH2), 120.15 (2 CH), 125.25 (CH), 125.28 (CH), 127.24 (2
CH), 127.90 (2 CH), 141.44 (2 C), 143.77 (C), 143.89 (C),
156.25 (CvO), 171.49 (CvO), 174.91 (CvO). ESI-MS: m/z =
692.6 [M + H]+, 709.7 [M + NH4]
+.
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Fmoc-Asp(O-C26H53)-OH (3i). A solution of Fmoc-Asp-OtBu
(1) (0.118 g, 0.288 mmol), MSNT (85.6 mg, 0.289 mmol) and
MeIm (24.2 mg, 0.295 mmol) in CH2Cl2 (25 mL) was stirred for
10 min and ceryl alcohol (0.100 g, 0.261 mmol) was added sub-
sequently. After stirring for 25 h at room temperature, the
mixture was partitioned between 2% aqueous citric acid and
CH2Cl2, washed with 2% citric acid, H2O and brine. The
organic layer was dried over Na2SO4 and evaporated to yield a
colourless solid, which was dissolved in CH2Cl2 (5 mL).
CF3COOH (6.25 mL) was added at 0 °C, the mixture stirred at
room temperature for 90 min, diluted with CH2Cl2 and washed
four times with water and once with brine. After drying over
Na2SO4 and removal of the solvent, the residue was purified by
flash chromatography (SiO2; petroleum ether/ethyl acetate [2 : 1]
+ 0.5% AcOH), affording 3i as a colourless solid, yield: 0.151 g
(80%), m.p. 99–101 °C. IR (ATR): ν = 3379, 2916, 2849, 2057,
1758, 1734, 1535, 1472, 1450, 1377, 1359, 1322, 1253, 1203,
1168, 1090, 1043, 989, 937, 860, 776, 755, 736, 718, 650 cm−1.
1H NMR (500 MHz, CDCl3): δ = 0.88 (t, J = 6.9 Hz, 3 H),
1.20–1.36 (m, 46 H), 1.59–1.69 (m, 2 H), 2.89 (dd, J = 17.4,
4.7 Hz, 1 H), 3.09 (dd, J = 17.4, 4.2 Hz, 1 H), 4.10–4.15 (m, 2
H), 4.24 (t, J = 7.1 Hz, 1 H), 4.34–4.38 (m, 1 H), 4.43–4.46 (m,
1 H), 4.68–4.71 (m, 1 H), 5.86 (d, J = 8.5 Hz, 1 H), 7.31 (t, J =
7.3 Hz, 2 H), 7.40 (t, J = 7.5 Hz, 2 H), 7.59 (d, J = 6.2 Hz, 2 H),
7.76 (d, J = 7.6 Hz, 2 H). 13C NMR and DEPT (125 MHz,
CDCl3): δ = 14.28 (CH3), 22.84 (CH2), 25.99 (CH2), 28.60
(CH2), 29.39 (CH2), 29.51 (CH2), 29.75 (CH2), 29.81 (CH2),
29.85 (16 CH2), 32.07 (CH2), 36.52 (CH2), 47.21 (CH), 50.23
(CH), 65.83 (CH2), 67.57 (CH2), 120.15 (2 CH), 125.24 (CH),
125.28 (CH), 127.24 (2 CH), 127.91 (2 CH), 141.44 (2 C),
143.77 (C), 143.89 (C), 156.24 (CvO), 171.54 (CvO), 174.31
(CvO). ESI-MS: m/z = 720.7 [M + H]+, 737.7 [M + NH4]
+.
Fmoc-Asp(O-Oleyl)-OH (3j). A solution of Fmoc-Asp-OtBu
(1) (5.43 g, 13.2 mmol), MSNT (3.91 g, 13.2 mmol) and MeIm
(1.08 g, 13.2 mmol) in CH2Cl2 (15 mL) was stirred for 10 min
and oleyl alcohol (2.50 g, 12.0 mmol) was added subsequently.
After stirring for 4 h at room temperature, the mixture was parti-
tioned between 2% aqueous citric acid and CH2Cl2, washed with
2% citric acid, H2O and brine. After drying over Na2SO4 and
removal of the solvent, the residue was purified by flash chrom-
atography (SiO2; petroleum ether/diethyl ether, 2 : 1), affording
the protected ester as a colourless solid, yield: 6.20 g (78%).
This product (6.00 g, 9.07 mmol) was dissolved in CH2Cl2
(25 mL). CF3COOH (15 mL) was added at 0 °C, the mixture
stirred at room temperature for 90 min, diluted with CH2Cl2 and
washed four times with water and once with brine. After drying
over Na2SO4 and removal of the solvent, the residue was
purified by flash chromatography (SiO2; petroleum ether/diethyl
ether [2 : 1] + 0.5% AcOH), affording 3j as a colourless solid,
yield: 4.56 g (83%). IR (ATR): ν = 3354, 3246, 3064, 3005,
2921, 2852, 2056, 1724, 1703, 1652, 1543, 1450, 1404, 1372,
1280, 1236, 1184, 1083, 994, 833, 810, 770, 734, 620 cm−1. 1H
NMR (500 MHz, CDCl3): δ = 0.88 (t, J = 6.9 Hz, 3 H),
1.26–1.37 (m, 22 H), 1.62–1.65 (m, 2 H), 1.99–2.02 (m, 4 H),
2.89 (dd, J = 4.2, 17.5 Hz, 1 H), 3.10 (dd, J = 3.8, 17.4 Hz,
1 H), 4.13 (t, J = 6.6 Hz, 2 H), 4.24 (t, J = 7.0 Hz, 1 H),
4.34–4.38 (m, 1 H), 4.43–4.46 (m, 1 H), 4.69–4.71 (m, 1 H),
5.32–5.36 (m, 2 H), 5.85 (br d, J = 8.3 Hz, 1 H), 7.32 (t, J =
7.4 Hz, 2 H), 7.40 (t, J = 7.4 Hz, 2 H), 7.60 (d, J = 5.7 Hz, 2 H),
7.76 (d, J = 7.5 Hz, 2 H).13C NMR and DEPT (125 MHz,
CDCl3): δ = 14.28 (CH3), 22.84 (CH2), 25.99 (CH2), 27.34
(CH2), 27.36 (CH2), 28.60 (CH2), 29.36 (2 CH2), 29.47 (2
CH2), 29.56 (CH2), 29.68 (CH2), 29.88 (CH2), 29.91 (CH2),
32.05 (CH2), 36.51 (CH2), 47.21 (CH), 50.25 (CH), 65.82
(CH2), 67.58 (CH2), 120.16 (2 CH), 125.28 (CH), 125.48 (CH),
127.24 (2 CH), 127.91 (2 CH), 129.91 (CH), 130.14 (CH),
141.44 (2 C), 143.77 (C), 143.89 (C), 156.24 (CvO), 171.52
(CvO), 174.81 (CvO). ESI-MS: m/z = 606.3 [M + H]+.
i-Bu-Lys(Cbz)-OtBu. Acetic acid (77 μL, 1.4 mmol), a solu-
tion of Lys(Cbz)-OtBu·HCl (21) (0.209 g, 0.561 mmol) and
EtN(i-Pr)2 (64 μL, 0.37 mmol) in methanol (4 mL), and finally
isobutyraldehyde (58 μL, 0.64 mmol) were added one after the
other to a solution of NaBH3CN (40.3 mg, 0.642 mmol) in
methanol (10 mL). The mixture was stirred at room temperature
for 2 h. The major part of methanol was removed and the
mixture was partitioned between ethyl acetate and K2CO3 (half-
sat. aqueous). The organic layer was washed with brine and
dried over Na2SO4. Removal of the solvent and flash chromato-
graphy (SiO2; petroleum ether/ethyl acetate, 2 : 3) afforded i-Bu-
Lys(Cbz)-OtBu as a colourless oil, yield: 0.194 g (92%). IR
(ATR): ν = 3329, 2948, 2933, 2867, 1771, 1723, 1709, 1653,
1531, 1452, 1395, 1367, 1338, 1243, 1150, 1081, 1048, 1027,
845, 777, 738, 696, 651 cm−1. 1H NMR (500 MHz, CDCl3): δ =
0.89 (d, J = 6.6 Hz, 6 H), 1.36–1.42 (m, 1 H), 1.46 (s, 9 H),
1.48–1.61 (m, 5 H), 1.64–1.71 (m, 1 H), 2.26 (dd, J = 11.1,
6.1 Hz, 1 H), 2.35 (dd, J = 11.1, 7.4 Hz, 1 H), 3.02 (t, J = 6.7
Hz, 1 H), 3.19 (q, J = 6.6 Hz, 2 H), 4.82 (br s, 1 H), 5.08 (s,
2 H), 7.29–7.37 (m, 5 H). 13C NMR and DEPT (125 MHz,
CDCl3): δ = 20.61 (CH3), 20.96 (CH3), 23.15 (CH2), 28.36 (3
CH3), 28.81 (CH), 29.82 (CH2), 33.28 (CH2), 41.01 (CH2),
56.32 (CH2), 62.41 (CH), 66.70 (CH2), 81.03 (C), 128.20 (2
CH), 128.24 (CH), 128.63 (2 CH), 136.76 (C), 156.48 (CvO),
175.14 (CvO). ESI-MS: m/z = 393.4 [M + H]+.
Benzyl 4-iodophenylacetate. Benzyl bromide (58 μL,
0.49 mmol) was added dropwise to a mixture of 4-iodophenyl-
acetic acid (0.101 g, 0.385 mmol) and Cs2CO3 (0.162 g,
0.497 mmol) in DMF (10 mL). The reaction mixture was stirred
at room temperature for 1 h and then partitioned between ethyl
acetate and H2O. The organic layer was washed twice with H2O,
once with brine and dried over Na2SO4. Removal of the solvent
and flash chromatography (SiO2; petroleum ether/ethyl acetate,
50 : 1 to 3 : 1) afforded benzyl 4-iodophenylacetate as a colour-
less solid, yield: 0.124 g (92%), m.p. 49–50 °C. IR (ATR): ν =
3031, 2955, 2893, 2056, 2030, 2010, 1918, 1844, 1771, 1722,
1684, 1635, 1485, 1457, 1416, 1399, 1330, 1216, 1165, 1058,
1006, 974, 911, 847, 796, 754, 699 cm−1. 1H NMR (500 MHz,
CDCl3): δ = 3.61 (s, 2 H), 5.14 (s, 2 H), 7.03 (d, J = 8.3 Hz,
2 H), 7.30–7.38 (m, 5 H), 7.65 (d, J = 8.3 Hz, 2 H). 13C NMR
and DEPT (125 MHz, CDCl3): δ = 40.93 (CH2), 66.96 (CH2),
92.83 (C), 128.35 (2 CH), 128.49 (CH), 128.73 (2 CH), 131.45
(2 CH), 133.61 (C), 135.75 (C), 137.79 (2 CH), 171.01 (CvO).
MS (EI): m/z (%) = 352 (28) [M+], 217 (84), 91 (100), 90 (20),
89 (17). Elemental analysis calcd for C15H13IO2: C 51.16,
H 3.72; found: C 51.24, H 3.70.
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 8216–8235 | 8227
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Benzyl 4-benzoylthiophenylacetate. Thiobenzoic acid
(0.8 mL, 6.8 mmol), EtN(i-Pr)2 (1.46 g, 2.83 mmol) and copper(I)
iodide (0.108 g, 0.567 mmol) were added to a solution of
benzyl 4-iodophenylacetate (1.99 g, 5.66 mmol) and 1,10-phe-
nanthroline (0.203 g, 1.13 mmol) in toluene (20 mL). The reac-
tion mixture was stirred at reflux for 18 h and then filtered
through a short path of Celite®. Removal of the solvent and
flash chromatography (SiO2; petroleum ether/ethyl acetate, 20 : 1
to 2 : 1) afforded benzyl 4-benzoylthiophenylacetate as a light
brown solid, yield: 1.73 g (84%), m.p. 130–131 °C. IR (ATR):
ν = 3348, 3094, 3057, 2988, 2913, 2842, 2056, 2030, 1844,
1771, 1734, 1704, 1692, 1618, 1585, 1516, 1475, 1457, 1437,
1409, 1369, 1340, 1308, 1274, 1246, 1213, 1164, 1144, 1058,
963, 934, 856, 843, 812, 756, 722, 680, 640, 612 cm−1. 1H
NMR (500 MHz, CDCl3): δ = 3.73 (s, 2 H), 5.15 (s, 2 H),
7.31–7.42 (m, 7 H), 7.46–7.52 (m, 4 H), 7.62 (t, J = 7.4 Hz,
1 H), 8.03 (d, J = 7.2 Hz, 2 H). 13C NMR and DEPT (125 MHz,
CDCl3): δ = 41.24 (CH2), 66.96 (CH2), 126.28 (C), 127.63
(2 CH), 128.35 (2 CH), 128.46 (CH), 128.74 (2 CH), 128.90 (2
CH), 130.41 (2 CH), 133.84 (CH), 135.39 (2 CH), 135.60 (C),
135.81 (C), 136.72 (C), 171.01 (CvO), 190.27 (CvO).
ESI-MS: m/z = 742.4 [2 M + NH4]
+. Elemental analysis
calcd for C22H18O3S: C 72.90, H 5.01, S 8.85; found: C 72.96,
H 5.10, S 8.84.
Benzyl 2-(4-(chlorosulfonyl)phenyl)acetate. A solution of
benzyltrimethylammonium chloride (0.993 g, 4.97 mmol) and
trichloroisocyanuric acid (0.527 g, 2.27 mmol) in acetonitrile
(9 mL) was stirred for 30 min and added to a solution of benzyl
4-benzoylthiophenylacetate (0.500 g, 1.42 mmol) in acetonitrile
(5 mL). The reaction mixture was stirred at 0 °C for 17 min, then
diluted with ethyl acetate, washed with a dil. aqueous solution of
K2CO3, brine and dried over Na2SO4. Removal of the solvent
and instantaneous flash chromatography (SiO2; petroleum ether/
ethyl acetate, 50 : 1 to 3 : 1) afforded benzyl 2-(4-(chlorosulfo-
nyl)phenyl)acetate as white crystals, yield: 0.364 g (79%), m.p.
57–58 °C. IR (ATR): ν = 3090, 3028, 2893, 2826, 2674, 2559,
1736, 1683, 1597, 1496, 1473, 1458, 1417, 1369, 1333, 1295,
1238, 1215, 1164, 1079, 1017, 989, 930, 859, 829, 806, 741,
703, 676 cm−1. 1H NMR (500 MHz, CDCl3): δ = 3.80 (s, 2 H),
5.16 (s, 2 H), 7.31–7.39 (m, 5 H), 7.54 (d, J = 8.6 Hz, 2 H),
8.00 (d, J = 8.6 Hz, 2 H). 13C NMR and DEPT (125 MHz,
CDCl3): δ = 41.22 (CH2), 67.40 (CH2), 127.41 (2 CH), 128.51
(2 CH), 128.72 (CH), 128.81 (2 CH), 130.85 (2 CH), 135.39
(C), 142.05 (C), 143.32 (C), 169.91 (CvO). ESI-MS: m/z =
322.7 [M − H]−.
22: EtN(i-Pr)2 (0.111 mL, 0.653 mmol) was added to a solu-
tion of iBu-Lys(Cbz)-OtBu (0.255 g, 0.65 mmol) and benzyl
2-(4-(chlorosulfonyl)phenyl)acetate (0.211 g, 0.65 mmol) in
CH2Cl2 (20 mL). The mixture was stirred at room temperature
for 3 d and then partitioned between CH2Cl2 and 2% aqueous
citric acid. The aqueous layer was extracted three times with
CH2Cl2 and the combined organic layers were washed with
brine and dried over Na2SO4. Removal of the solvent and flash
chromatography (SiO2; pentane/ethyl acetate, 2 : 3) afforded 22
as a colourless oil, yield: 0.280 g (63%). IR (ATR): ν = 3389,
2959, 2929, 2870, 1724, 1651, 1529, 1454, 1395, 1368, 1337,
1242, 1149, 1089, 998, 845, 813, 735, 697, 677 cm−1. 1H NMR
(500 MHz, CDCl3): δ = 0.85 (d, J = 6.6 Hz, 3 H), 0.90 (d, J =
6.6 Hz, 3 H), 1.29 (s, 9 H), 1.44–1.62 (m, 5 H), 1.85–1.99 (m,
2 H), 2.95 (dd, J = 14.5, 7.4 Hz, 1 H), 3.06–3.17 (m, 3 H), 3.70
(s, 2 H), 4.23 (t, J = 7.3 Hz, 1 H), 4.86 (br s, 1 H), 5.10 (s, 2 H),
5.12 (s, 2 H), 7.29–7.40 (m, 12 H), 7.78 (d, J = 8.3 Hz, 2 H).
13C NMR and DEPT (125 MHz, CDCl3): δ = 20.33 (CH3),
20.39 (CH3), 23.65 (CH2), 27.78 (3 CH3), 28.03 (CH), 29.34
(CH2), 30.28 (CH2), 40.71 (CH2), 40.93 (CH2), 53.86 (CH2),
60.76 (CH), 66.53 (CH2), 66.99 (CH2), 82.02 (C), 127.77
(2 CH), 128.06 (CH), 128.08 (CH), 128.26 (2 CH), 128.43 (2
CH), 128.49 (2 CH), 128.61 (2 CH), 129.84 (2 CH), 135.40 (C),
136.62 (C), 138.61 (C), 139.12 (C), 156.36 (CvO), 169.62
(CvO), 170.34 (CvO). ESI-MS: m/z = 698.6 [M + NH4]
+.
23: Compound 22 (89.3 mg, 0.132 mmol) and palladium on
activated carbon (90 mg, 10 wt%) in ethyl acetate (10 mL) were
stirred under hydrogen (1 atm) at room temperature for 23 h. Fil-
tration of the reaction mixture through a short path of Celite®
and removal of the solvent afforded 23 as a colourless, viscous
oil, yield: 56.9 mg (95%). IR (ATR): ν = 3055, 2959, 2929,
2870, 2056, 2030, 1917, 1770, 1728, 1631, 1577, 1460, 1431,
1366, 1336, 1256, 1152, 1089, 1025, 992, 920, 846, 788, 723,
701, 675 cm−1. 1H NMR (500 MHz, methanol-d4): δ = 0.92 (d,
J = 6.6 Hz, 3 H), 0.95 (d, J = 6.6 Hz, 3 H), 1.11–1.19 (m, 1 H),
1.23–1.32 (m, 2 H), 1.38 (s, 9 H), 1.42–1.54 (m, 2 H),
1.83–2.00 (m, 2 H), 2.65–2.77 (m, 2 H), 3.00 (dd, J = 14.4, 7.4
Hz, 1 H), 3.13 (dd, J = 14.5, 7.3 Hz, 1 H), 3.63 (s, 2 H), 4.13 (t,
J = 7.3 Hz, 1 H), 7.52 (d, J = 8.3 Hz, 2 H), 7.78 (d, J = 8.3 Hz,
2 H). 13C NMR and DEPT (125 MHz, methanol-d4): δ = 20.76
(CH3), 20.82 (CH3), 24.65 (CH2), 28.10 (CH2), 28.16 (3 CH3),
29.11 (CH), 30.57 (CH2), 40.50 (CH2), 44.24 (CH2), 55.86
(CH2), 62.06 (CH), 83.31 (C), 128.53 (2 CH), 131.23 (2 CH),
139.89 (C), 143.66 (C), 171.16 2 CvO. ESI-MS: m/z = 457.3
[M + H]+, 479.3 [M + Na]+, 913.6 [2 M + H]+, 935.6
[2 M + Na]+.
24: N-(FmocO)succinimide (0.239 g, 0.708 mmol) was added
to a solution of 23 (0.216 g, 0.473 mmol) in acetonitrile (4 mL),
THF (4 mL) and K2CO3 (1 M aqueous, 4 mL). The reaction
mixture was stirred at room temperature for 17 h and then parti-
tioned between CH2Cl2 and 2% aqueous citric acid. The organic
layer was washed with 2% citric acid, H2O and brine and dried
over Na2SO4. Removal of the solvent and flash chromatography
(SiO2; petroleum ether/[CH2Cl2/MeOH 10 : 1] + 0.5% AcOH,
20 : 1 to 1 : 1) afforded 24 as a colourless, viscous oil, yield:
0.163 g (51%). IR (ATR): ν = 3369, 3067, 2958, 2929, 2869,
1844, 1723, 1530, 1450, 1416, 1393, 1367, 1336, 1247, 1152,
1089, 999, 938, 845, 813, 759, 740, 651 cm−1. 1H NMR
(500 MHz, CDCl3): δ = 0.92 (t, J = 7.7 Hz, 6 H), 1.02–1.11 (m,
1 H), 1.24–1.34 (m, 4 H), 1.38 (s, 9 H), 1.78–1.86 (m, 1 H),
1.89–1.96 (m, 1 H), 2.90–3.06 (m, 4 H), 3.66 (s, 2 H), 4.12 (t, J
= 7.2 Hz, 1 H), 4.20 (t, J = 6.7 Hz, 1 H), 4.41 (d, J = 6.8 Hz,
2 H), 4.84 (br t, J = 5.3 Hz, 1 H), 7.31 (t, J = 7.4 Hz, 2 H),
7.38–7.44 (m, 4 H), 7.58 (d, J = 7.4 Hz, 2 H), 7.75–7.79 (m,
4 H). 13C NMR and DEPT (125 MHz, CDCl3): δ = 20.55
(CH3), 20.57 (CH3), 24.00 (CH2), 27.97 (3 CH3), 28.05 (CH),
29.42 (2 CH2), 40.90 (CH2), 41.24 (CH2), 47.30 (CH), 53.73
(CH2), 60.63 (CH), 66.95 (CH2), 82.30 (C), 120.13 (2 CH),
125.15 (2 CH), 127.20 (2 CH), 127.70 (2 CH), 127.84 (2 CH),
130.11 (2 CH), 139.02 (C), 139.45 (C), 141.44 (2 C), 143.99
(2 C), 157.00 (CvO), 170.01 (CvO), 173.79 (CvO). ESI-MS:
m/z = 679.5 [M + H]+, 696.3 [M + NH4]
+, 701.6 [M + Na]+.
8228 | Org. Biomol. Chem., 2012, 10, 8216–8235 This journal is © The Royal Society of Chemistry 2012
Pu
bl
is
he
d 
on
 0
3 
A
ug
us
t 2
01
2.
 D
ow
nl
oa
de
d 
by
 S
L
U
B
 D
R
E
SD
E
N
 o
n 
26
/0
3/
20
14
 1
0:
17
:5
5.
 
View Article Online
25: EtN(i-Pr)2 (1.25 g, 9.61 mmol) and 4-toluenesulfonyl
chloride (1.22 g, 6.42 mmol) were added to a solution of i-Bu-
Lys(Cbz)-OtBu (2.52 g, 6.42 mmol) in CH2Cl2 (60 mL). The
mixture was stirred at room temperature for 5 d and then parti-
tioned between CH2Cl2 and 2% aqueous citric acid. The
aqueous layer was extracted three times with CH2Cl2, the com-
bined organic layers were washed with brine and dried over
Na2SO4. Removal of the solvent and flash chromatography
(SiO2; petroleum ether/ethyl acetate, 1 : 1) afforded 25 as a col-
ourless solid, yield: 3.07 g (88%), m.p. 54–56 °C. IR (ATR): ν =
3398, 2952, 2872, 1727, 1710, 1686, 1653, 1617, 1596, 1558,
1528, 1456, 1395, 1367, 1336, 1308, 1244, 1230, 1147, 1111,
1088, 1013, 951, 866, 841, 816, 762, 718, 706, 661 cm−1. 1H
NMR (600 MHz, CDCl3): δ = 0.84 (d, J = 6.6 Hz, 3 H), 0.90 (d,
J = 6.6 Hz, 3 H), 1.30 (s, 9 H), 1.36–1.40 (m, 1 H), 1.46–1.63
(m, 4 H), 1.85–1.99 (m, 2 H), 2.40 (s, 3 H), 2.94 (dd, J = 14.6,
7.7 Hz, 1 H), 3.10 (dd, J = 14.6, 7.7 Hz, 1 H), 3.17 (q, J =
6.7 Hz, 2 H), 4.25 (t, J = 7.3 Hz, 1 H), 4.79 (br s, 1 H), 5.09 (s,
2 H), 7.27 (d, J = 7.2 Hz, 2 H), 7.29–7.38 (m, 5 H), 7.71 (d, J =
8.3 Hz, 2 H). 13C NMR and DEPT (150 MHz, CDCl3): δ =
20.52 (2 CH3), 21.61 (CH3), 23.82 (CH2), 27.95 (3 CH3), 28.37
(CH), 29.53 (CH2), 30.62 (CH2), 40.91 (CH2), 53.91 (CH2),
60.84 (CH), 66.73 (CH2), 82.08 (C), 127.75 (2 CH), 128.22
(CH), 128.24 (CH), 128.66 (2 CH), 129.58 (3 CH), 136.79 (C),
137.44 (C), 143.30 (C), 156.51 (CvO), 169.89 (CvO).
ESI-MS: m/z = 547.8 [M + H]+, 564.7 [M + NH4]
+.
26: Compound 25 (0.101 g, 0.185 mmol) and palladium on
activated carbon (50 mg, 10 wt%) in ethyl acetate (15 mL) were
stirred under hydrogen (1 atm) at room temperature for 24 h. Fil-
tration of the reaction mixture through a short path of Celite®
and removal of the solvent afforded 26 as a light yellow oil,
yield: 75.4 mg (99%). IR (ATR): ν = 2987, 2932, 2870, 1727,
1673, 1654, 1598, 1534, 1493, 1464, 1451, 1394, 1367, 1338,
1250, 1151, 1089, 996, 937, 845, 814, 719, 664, 656 cm−1. 1H
NMR (500 MHz, CDCl3/methanol-d4, 3 : 1): δ = 0.66 (d, J = 6.6
Hz, 3 H), 0.71 (d, J = 6.7 Hz, 3 H), 1.11 (s, 9 H), 1.14–1.20 (m,
2 H), 1.22–1.34 (m, 2 H), 1.36–1.46 (m, 1 H), 1.65–1.80 (m,
2 H), 2.22 (s, 3 H), 2.44 (t, J = 7.2 Hz, 2 H), 2.75 (dd, J = 14.7,
7.4 Hz, 1 H), 2.90 (dd, J = 14.7, 7.6 Hz, 1 H), 4.04 (t, J =
7.4 Hz, 1 H), 7.11 (d, J = 8.2 Hz, 2 H), 7.51 (d, J = 8.2 Hz,
2 H). 13C NMR and DEPT (125 MHz, CDCl3/methanol-d4,
3 : 1): δ = 20.48 (CH3), 20.53 (CH3), 21.54 (CH3), 24.14 (CH2),
27.92 (3 CH3), 28.43 (CH), 30.91 (CH2), 32.71 (CH2), 41.56
(CH2), 54.17 (CH2), 61.21 (CH), 82.55 (C), 127.84 (2 CH),
129.88 (2 CH), 137.25 (C), 143.93 (C), 170.18 (CvO).
ESI-MS: m/z = 413.4 [M + H]+.
(S)-tert-Butyl 6-(2-(4-(2-benzyloxy-2-oxoethyl)phenoxy)acet-
amido)-2-(N-isobutyl-4-methylphenylsulfonamido)hexanoate. A
catalytic amount of DMAP was added to a solution of 26
(92.3 mg, 0.224 mmol), 27 (0.100 g, 0.333 mmol) and
EDC·HCl (64.3 mg, 0.335 mmol) in CH2Cl2 (10 mL). The reac-
tion mixture was stirred at room temperature for 5 d, then diluted
with CH2Cl2, washed three times with H2O, once with brine and
dried over Na2SO4. Removal of the solvent and flash chromato-
graphy (SiO2; pentane/ethyl acetate, 5 : 1 to 2 : 3) afforded
(S)-tert-butyl 6-(2-(4-(2-benzyloxy-2-oxoethyl)phenoxy)acet-
amido)-2-(N-isobutyl-4-methylphenylsulfonamido)hexanoate as
a colourless solid, yield: 87.4 mg (56%), m.p. 72–74 °C. IR
(ATR): ν = 3304, 2931, 2864, 1726, 1674, 1595, 1537, 1512,
1450, 1395, 1368, 1337, 1305, 1243, 1152, 1088, 1057, 1001,
843, 815, 740, 721, 697 cm−1. 1H NMR (500 MHz, CDCl3): δ =
0.84 (d, J = 6.6 Hz, 3 H), 0.89 (d, J = 6.6 Hz, 3 H), 1.29 (s,
9 H), 1.37–1.47 (m, 1 H), 1.51–1.67 (m, 4 H), 1.85–1.99 (m,
2 H), 2.40 (s, 3 H), 2.94 (dd, J = 14.7, 7.4 Hz, 1 H), 3.10 (dd,
J = 14.7, 7.6 Hz, 1 H), 3.33 (q, J = 6.7 Hz, 2 H), 3.62 (s, 2 H),
4.28 (t, J = 7.4 Hz, 1 H), 4.46 (s, 2 H), 5.13 (s, 2 H), 6.66 (br t,
J = 5.6 Hz, 1 H), 6.89 (d, J = 8.7 Hz, 2 H), 7.23 (d, J = 8.7 Hz,
2 H), 7.27 (d, J = 8.5 Hz, 2 H), 7.30–7.37 (m, 5 H), 7.71 (d, J =
8.3 Hz, 2 H). 13C NMR and DEPT (125 MHz, CDCl3): δ =
20.51 (CH3), 20.57 (CH3), 21.61 (CH3), 23.89 (CH2), 27.92 (3
CH3), 28.27 (CH), 29.10 (CH2), 30.61 (CH2), 38.93 (CH2),
40.49 (CH2), 53.88 (CH2), 60.74 (CH), 66.81 (CH2), 67.55
(CH2), 82.08 (C), 114.96 (2 CH), 127.65 (C), 127.74 (2 CH),
128.31 (2 CH), 128.41 (CH), 128.70 (2 CH), 129.57 (2 CH),
130.81 (2 CH), 135.90 (C), 137.34 (C), 143.32 (C), 156.51 (C),
168.25 (CvO), 169.83 (CvO), 171.67 (CvO). ESI-MS: m/z =
695.4 [M + H]+, 712.6 [M + NH4]
+.
28: (S)-tert-Butyl 6-(2-(4-(2-benzyloxy-2-oxoethyl)phenoxy)-
acetamido)-2-(N-isobutyl-4-methylphenylsulfonamido)hexanoate
(0.143 g, 0.206 mmol) and palladium on activated carbon
(14 mg, 10 wt%) in ethyl acetate (10 mL) were stirred under
hydrogen (1 atm) at room temperature for 2 h. Filtration of the
reaction mixture through a short path of Celite® and removal of
the solvent afforded 28 as a colourless solid, yield: 0.125 g
(100%), m.p. 47–49 °C. IR (ATR): ν = 3364, 2957, 2933, 2870,
1725, 1641, 1611, 1569, 1555, 1512, 1449, 1394, 1367, 1337,
1291, 1239, 1152, 1089, 1062, 1000, 940, 843, 813, 720,
664 cm−1. 1H NMR (500 MHz, CDCl3/methanol-d4, 3 : 1): δ =
0.69 (d, J = 6.6 Hz, 3 H), 0.75 (d, J = 6.6 Hz, 3 H), 1.15 (s,
9 H), 1.21–1.31 (m, 2 H), 1.37–1.51 (m, 3 H), 1.71–1.83 (m,
2 H), 2.26 (s, 3 H), 2.79 (dd, J = 14.7, 7.4 Hz, 1 H), 2.94 (dd, J
= 14.7, 7.6 Hz, 1 H), 3.15 (td, J = 7.0, 2.5 Hz, 2 H), 3.41 (s,
2 H), 4.09 (t, J = 7.4 Hz, 1 H), 4.30 (s, 2 H), 6.76 (d, J =
8.7 Hz, 2 H), 7.08 (d, J = 8.7 Hz, 2 H), 7.15 (d, J = 8.2 Hz,
2 H), 7.55 (d, J = 8.2 Hz, 2 H). 13C NMR and DEPT (125 MHz,
CDCl3/methanol-d4, 3 : 1): δ = 19.90 (CH3), 19.97 (CH3), 21.00
(CH3), 23.45 (CH2), 27.34 (3 CH3), 27.81 (CH), 28.46 (CH2),
30.10 (CH2), 38.49 (CH2), 39.95 (CH2), 53.55 (CH2), 60.43
(CH), 66.89 (CH2), 81.95 (C), 114.47 (2 CH), 127.23 (2 CH),
127.75 (C), 129.27 (2 CH), 130.33 (2 CH), 136.60 (C), 143.28
(C), 156.03 (C), 168.74 (CvO), 169.50 (CvO), 174.08
(CvO). ESI-MS: m/z = 603.1 [M − H]−.
Benzyl 4-(2-tert-butoxy-2-oxoethoxy)phenylacetate. tert-Butyl
bromoacetate (4.00 mL, 27.1 mmol) was added dropwise to a
mixture of benzyl 4-hydroxyphenylacetate (6.57 g, 27.1 mmol)
and Cs2CO3 (13.3 g, 40.7 mmol) in DMF (60 mL). The reaction
mixture was stirred at room temperature for 5 h. The reaction
mixture was diluted with ethyl acetate and washed four times
with water and once with brine. The organic layer was dried over
Na2SO4. Removal of the solvent and flash chromatography
(SiO2; pentane/ethyl acetate, 20 : 1 to 3 : 2) afforded benzyl 4-(2-
tert-butoxy-2-oxoethoxy)phenylacetate as a colourless oil, yield:
9.15 g (95%). IR (ATR): ν = 3065, 3031, 2978, 2934, 2056,
1918, 1869, 1844, 1828, 1727, 1651, 1611, 1558, 1541, 1512,
1454, 1369, 1303, 1216, 1145, 1079, 982, 842, 737, 697 cm−1.
1H NMR (500 MHz, CDCl3): δ = 1.49 (s, 9 H), 3.61 (s, 2 H),
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 8216–8235 | 8229
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4.50 (s, 2 H), 5.12 (s, 2 H), 6.85 (d, J = 8.7 Hz, 2 H), 7.20 (d,
J = 8.7 Hz, 2 H), 7.30–7.37 (m, 5 H). 13C NMR and DEPT
(125 MHz, CDCl3): δ = 28.19 (3 CH3), 40.59 (CH2), 65.89
(CH2), 66.74 (CH2), 82.52 (C), 114.85 (2 CH), 127.01 (C),
128.28 (2 CH), 128.36 (CH), 128.69 (2 CH), 130.53 (2 CH),
135.98 (C), 157.21 (C), 168.16 (CvO), 171.76 (CvO).
ESI-MS: m/z = 374.2 [M + NH4]
+, 730.5 [2 M + NH4]
+.
27: Trifluoroacetic acid (60 mL) was added slowly at 0 °C to a
solution of benzyl 4-(2-tert-butoxy-2-oxoethoxy)phenylacetate
(1.28 g, 3.57 mmol) in CH2Cl2 (60 mL). The mixture was stirred
at room temperature for 90 min, diluted with CH2Cl2 and
washed four times with water and once with brine. Drying over
Na2SO4 and removal of the solvent afforded 27 as a light yellow
solid, yield: 0.815 g (76%), m.p. 103–104 °C. IR (ATR): ν =
3058, 3035, 2922, 2890, 2774, 1917, 1870, 1844, 1726, 1651,
1610, 1588, 1511, 1421, 1379, 1347, 1308, 1253, 1224, 1158,
1083, 984, 940, 907, 838, 807, 774, 741, 694 cm−1. 1H NMR
(600 MHz, CDCl3): δ = 3.62 (s, 2 H), 4.67 (s, 2 H), 5.13 (s, 2
H), 6.88 (d, J = 8.6 Hz, 2 H), 7.23 (d, J = 8.6 Hz, 2 H),
7.30–7.37 (m, 5 H). 13C NMR and DEPT (150 MHz, CDCl3):
δ = 40.54 (CH2), 65.04 (CH2), 66.84 (CH2), 114.94 (2 CH),
127.73 (C), 128.31 (2 CH), 128.41 (CH), 128.71 (2 CH), 130.76
(2 CH), 135.91 (C), 156.67 (C), 171.74 (CvO), 173.12 (CvO).
ESI-MS: m/z = 318.1 [M + NH4]
+, 618.0 [2 M + NH4]
+, 623.1
[2 M + Na]+. Elemental analysis calcd for C17H16O5: C 67.99, H
5.37; found: C 68.13, H 5.34.
32: A solution of 3,5-dichloro-2-hydroxyacetophenone (29)
(1.00 g, 4.88 mmol) and 4-hydrazinobenzoic acid (30) (0.742 g,
4.88 mmol) in ethanol (90 mL) and AcOH (0.25 mL) was stirred
at reflux for 2.5 h. During the reaction, brown crystals precipi-
tated and were collected by filtration of the hot reaction mixture.
The filtrate was concentrated, ethanol (30 mL) was added, the
mixture was heated at reflux and filtered immediately. These
steps were repeated (10 mL ethanol). After drying 32 was
obtained as brown crystals, yield: 1.09 g (66%), m.p.
299–301 °C. IR (ATR): ν = 3379, 2078, 2790, 2530, 2053,
1661, 1600, 1577, 1518, 1451, 1420, 1290, 1251, 1163, 1120,
939, 839, 766, 737, 684 cm−1. 1H NMR (500 MHz, DMSO-d6):
δ = 2.43 (s, 3 H), 7.12 (d, J = 8.7 Hz, 2 H), 7.55 (s, 1 H), 7.60
(s, 1 H), 7.91 (d, J = 8.7 Hz, 2 H), 10.21 (s, 1 H), 12.50 (br s,
1 H), 13.56 (s, 1 H). 13C NMR and DEPT (125 MHz, DMSO-d6):
δ = 13.63 (CH3), 111.88 (2 CH), 121.33 (C), 122.03 (C), 122.47
(C), 125.99 (CH), 129.03 (CH), 131.38 (2 CH), 147.62 (C),
148.00 (C), 152.02 (C), 167.06 (CvO, CvN). ESI-MS: m/z =
339.1 [M + H]+. Elemental analysis calcd for C15H12Cl2N2O3:
C 53.12, H 3.57, N 8.26; found: C 52.86, H 3.54, N 8.18.
33: A solution of 3,5-dichloro-2-hydroxyacetophenone (29)
(1.00 g, 4.88 mmol) and 4-hydrazinophenylacetic acid36 (31)
(0.811 g, 4.87 mmol) in ethanol (90 mL) and AcOH (0.25 mL)
was stirred and heated at reflux for 2.5 h. The solvent was
removed and the residue recrystallised from ethyl acetate
(100 mL) and i-hexane (600 mL). After drying 33 was obtained
as orange crystals, yield: 0.881 g (51%), m.p. 231–233 °C. IR
(ATR): ν = 3371, 3077, 3031, 2906, 2731, 2635, 2566, 2056,
1733, 1704, 1652, 1619, 1585, 1517, 1454, 1424, 1366, 1301,
1244, 1198, 1174, 1116, 954, 853, 822, 799, 736 cm−1. 1H
NMR (500 MHz, acetone-d6): δ = 2.46 (s, 3 H), 3.58 (s, 2 H),
7.09 (d, J = 8.5 Hz, 2 H), 7.30 (d, J = 8.5 Hz, 2 H), 7.38 (d, J =
2.4 Hz, 1 H), 7.52 (d, J = 2.4 Hz, 1 H), 9.16 (s, 1 H), 10.71
(br s, 1 H), 13.67 (s, 1 H). 13C NMR and DEPT (125 MHz,
acetone-d6): δ = 12.79 (CH3), 40.47 (CH2), 113.81 (2 CH),
115.85 (C), 122.67 (C), 123.50 (C), 126.15 (CH), 128.31 (C),
129.47 (CH), 131.31 (2 CH), 136.20 (C), 153.30 (C), 172.93
(CvO), one carbon signal missing. ESI-MS: m/z = 353.2
[M + H]+.
tert-Butyl 4-hydroxyphenylacetate (35). A mixture of 4-hydro-
xyphenylacetic acid (34) (2.00 g, 13.2 mmol), tert-butyl aceto-
acetate (14 mL, 84.4 mmol) and conc. H2SO4 (0.104 g,
1.06 mmol) was stirred in a sealed tube at room temperature for
45 h and then diluted with diethyl ether. The organic layer was
washed twice with H2O, twice with NaHCO3 (dil. aqueous),
once with brine and dried over MgSO4. Removal of the solvent
and flash chromatography (SiO2; pentane/ethyl acetate, 8 : 1 to
6 : 1) afforded tert-butyl 4-hydroxyphenylacetate (35) as a col-
ourless solid, yield: 1.14 g (41%), m.p. 92–93 °C. IR (ATR): ν =
3306, 3007, 2980, 2934, 2056, 2030, 2009, 1917, 1871, 1844,
1771, 1734, 1717, 1693, 1653, 1613, 1593, 1559, 1515, 1446,
1369, 1313, 1269, 1221, 1166, 1129, 954, 859, 826, 808, 767,
711, 665 cm−1. 1H NMR (500 MHz, CDCl3): δ = 1.44 (s, 9 H),
3.45 (s, 2 H), 5.15 (s, 1 H), 6.74 (d, J = 8.5 Hz, 2 H), 7.11 (d,
J = 8.5 Hz, 2 H). 13C NMR and DEPT (125 MHz, CDCl3):
δ = 28.17 (3 CH3), 41.86 (CH2), 81.13 (C), 115.54 (2 CH),
126.67 (C), 130.50 (2 CH), 154.81 (C), 171.97 (CvO).
MS (EI): m/z (%) = 208 (13) [M+], 107 (93), 77 (16), 57 (100),
41 (19).
36: A mixture of tert-butyl 4-hydroxyphenylacetate (35)
(1.12 g, 5.38 mmol) and 5-fluoro-2-nitrobenzaldehyde (0.915 g,
5.38 mmol), K2CO3 (0.901 g, 6.45 mmol) in DMF (46 mL) was
stirred at 120 °C for 45 min. The reaction mixture was parti-
tioned between 2% aqueous citric acid and ethyl acetate. The
organic layer was washed three times with H2O, once with brine
and dried over MgSO4. Removal of the solvent and flash chrom-
atography (SiO2; pentane/ethyl acetate, 30 : 1 to 6 : 1) afforded
36 as a yellow solid, yield: 1.20 g (63%), m.p. 69–70 °C. IR
(ATR): ν = 3104, 3072, 2978, 2929, 2056, 2031, 1771, 1727,
1697, 1653, 1624, 1581, 1541, 1510, 1469, 1417, 1365, 1326,
1296, 1270, 1230, 1203, 1140, 1067, 1019, 966, 936, 878, 849,
808, 757, 681, 643 cm−1. 1H NMR (500 MHz, CDCl3): δ = 1.46
(s, 9 H), 3.57 (s, 2 H), 7.04 (d, J = 8.5 Hz, 2 H), 7.20 (d, J =
9.0 Hz, 1 H), 7.34–7.36 (m, 3 H), 8.15 (d, J = 9.0 Hz, 1 H),
10.43 (s, 1 H). 13C NMR and DEPT (125 MHz, CDCl3): δ =
28.19 (3 CH3), 41.95 (CH2), 81.38 (C), 116.91 (CH), 120.70
(2 CH), 127.49 (CH), 131.53 (2 CH), 131.67 (CH), 132.66 (C),
134.56 (C), 143.35 (C), 153.13 (C), 163.09 (C), 170.75 (C),
188.20 (CHO). ESI-MS: m/z = 375.2 [M + NH4]
+, 732.3 [2 M +
NH4]
+. Elemental analysis calcd for C19H19NO6: C 63.86,
H 5.36, N 3.92; found: C 63.92, H 5.37, N 3.91.
38: NaBH3CN (0.137 g, 2.18 mmol) was added to a solution
of 36 (0.688 g, 1.93 mmol) and 37 (0.540 g, 1.93 mmol) in
AcOH (114 μL, 1.99 mmol) and CH2Cl2 (20 mL). The reaction
mixture was stirred at room temperature for 17 h and then treated
with 1 M HCl (12 mL) for 10 min. After addition of 1 M NaOH
(16 mL), the layers were separated, and the aqueous layer was
extracted twice with CH2Cl2. The combined organic layers were
washed with brine and dried over MgSO4. Removal of the
solvent and flash chromatography (SiO2; pentane/ethyl acetate,
10 : 1 to 2 : 3) afforded 38 as a yellow, viscous oil, yield: 0.998 g
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(83%). IR (ATR): ν = 3432, 2924, 2852, 2056, 2030, 1843,
1729, 1611, 1581, 1558, 1540, 1515, 1473, 1448, 1419, 1365,
1339, 1256, 1226, 1141, 1101, 1017, 957, 892, 830, 754,
694 cm−1. 1H NMR (500 MHz, CDCl3): δ = 0.98–1.85 (m,
32 H), 2.24–2.36 (m, 2 H), 2.42–2.53 (m, 1 H), 2.78 (s, 0.4 ×
3 H), 2.80 (s, 0.6 × 3 H), 3.54 (s, 2 H), 3.57–3.60 (m, 0.6 H),
3.96–4.05 (m, 2 H), 4.40–4.44 (m, 0.4 H), 6.80–6.84 (m, 1 H),
7.02 (d, J = 8.5 Hz, 2 H), 7.23 (d, J = 7.6 Hz, 1 H), 7.30 (d, J =
8.5 Hz, 2 H), 7.94 (d, J = 9.0 Hz, 1 H). ESI-MS: m/z = 622.6
[M + H]+, 1243.8 [2 M + H]+.
39: Compound 38 (0.859 g, 1.38 mmol) and palladium on
activated carbon (0.127 g, 10 wt%) in methanol (14 mL) were
stirred under hydrogen (1 atm) at room temperature for 2 h. Fil-
tration of the reaction mixture through a short path of Celite®
and removal of the solvent afforded 39 as a yellow oil, yield:
0.772 g (94%). IR (ATR): ν = 3415, 3321, 2924, 2852, 2056,
2026, 2007, 1727, 1684, 1624, 1576, 1558, 1541, 1447, 1366,
1295, 1222, 1138, 1101, 1015, 954, 888, 810, 755 cm−1. 1H
NMR (500 MHz, CDCl3): δ = 0.99–1.85 (m, 34 H), 2.24–2.37
(m, 2 H), 2.38–2.55 (m, 1 H), 2.78 (s, 0.4 × 3 H), 2.79 (s, 0.6 ×
3 H), 3.47 (s, 2 H), 3.48–3.51 (m, 0.4 H), 3.68–3.76 (m, 2 H),
4.40–4.45 (m, 0.6 H), 6.62 (dd, J = 8.2, 3.4 Hz, 1 H), 6.76–6.81
(m, 2 H), 6.85 (d, J = 8.6 Hz, 2 H), 7.16 (d, J = 8.6 Hz, 2 H).
ESI-MS: m/z = 592.5 [M + H]+.
40: A solution of 39 (0.888 g, 1.50 mmol) and cyanogen
bromide (0.240 g, 2.27 mmol) in ethanol (30 mL) was stirred at
reflux for 17 h. After removal of the solvent, the residue was
purified by flash chromatography (SiO2; pentane/[CH2Cl2/
methanol 10 : 1], 5 : 1 to 2 : 3) to afford 40 as a light brown
solid, yield: 0.775 g (84%), m.p. 112–113 °C. IR (ATR): ν =
3127, 2972, 2926, 2853, 1844, 1726, 1658, 1618, 1557, 1496,
1448, 1414, 1366, 1314, 1236, 1216, 1140, 1102, 1015, 955,
875, 825 cm−1. 1H NMR (500 MHz, CDCl3): δ = 0.85–1.87 (m,
32 H), 2.02–2.18 (m, 2 H), 2.59–2.71 (m, 1 H), 2.80 (s, 0.4 ×
3 H), 2.86 (s, 0.6 × 3 H), 3.51 (s, 2 H), 4.11–4.21 (m, 2.4 H),
4.34–4.45 (m, 0.6 H), 6.70 (d, J = 3.1 Hz, 1 H), 6.02–6.94 (m,
3 H), 7.19 (d, J = 8.7 Hz, 1 H), 7.22 (d, J = 8.5 Hz, 2 H), 8.17
(br s, 2 H). ESI-MS: m/z = 617.6 [M + H]+.
41: A mixture of 40 (0.245 g, 0.397 mmol), silica gel (2.0 g)
and toluene (13 mL) was stirred at reflux for 3.5 h. The reaction
mixture was diluted with CH2Cl2/methanol (10 : 1) and filtered
through a short path of Celite®. After removal of the solvent,
compound 41 was obtained as a light yellow solid, yield:
0.220 g (99%), m.p. 145–146 °C. IR (ATR): ν = 3306, 3121,
2924, 2853, 2029, 1724, 1658, 1616, 1558, 1495, 1447, 1410,
1314, 1235, 1214, 1166, 1146, 1099, 1017, 955, 891, 803 cm−1.
1H NMR (500 MHz, CDCl3): δ = 0.86–1.87 (m, 23 H),
2.01–2.06 (m, 0.5 × 2 H), 2.18–2.22 (m, 0.5 × 2 H), 2.59–2.65
(m, 1 H), 2.79 (s, 0.5 × 3 H), 2.85 (s, 0.5 × 3 H), 3.47–3.53 (m,
0.5 H), 3.61 (s, 2 H), 4.10–4.24 (m, 2 H), 4.32–4.35 (m, 0.5 H),
6.70–6.74 (m, 1 H), 6.86–6.93 (m, 3 H), 7.13 (d, J = 8.4 Hz,
1 H), 7.22–7.25 (m, 2 H), 8.11 (br s, 2 H), 11.58 (br s, 1 H).
ESI-MS: m/z = 561.5 [M + H]+.
44: To a solution of Fmoc-Glu-OtBu (43) (0.430 g,
1.01 mmol) and HATU (0.384 g, 1.01 mmol) in CH2Cl2
(15 mL) was added EtN(i-Pr)2 (172 μL, 1.01 mmol). After stir-
ring at room temperature for 10 min, 42 (0.224 g, 0.537 mmol)
and EtN(i-Pr)2 (223 μL, 1.31 mmol) were added. After stirring
for 18 h at room temperature, the mixture was partitioned
between 2% aqueous citric acid and CH2Cl2, washed with 2%
citric acid, H2O and brine. The organic layer was dried over
Na2SO4 and evaporated. The residue was purified by flash
chromatography (SiO2; pentane/[CH2Cl2/methanol 10 : 1], 10 : 1
to 2 : 3) to yield a colourless solid, yield: 0.249 g (61%). This
solid (0.139 g, 0.185 mmol) was dissolved in CH2Cl2 (5 mL).
CF3COOH (5 mL) was added at 0 °C, and the mixture stirred at
room temperature for 90 min, diluted with CH2Cl2 and washed
four times with water and once with brine. After drying over
Na2SO4 and removal of the solvent, compound 44 was obtained
as a colourless solid, yield: 0.118 g (93%), m.p. 152–154 °C. IR
(ATR): ν = 3272, 3067, 2931, 2857, 1770, 1694, 1632, 1583,
1533, 1490, 1475, 1447, 1387, 1340, 1226, 1156, 1050, 951,
891, 823, 778, 757, 739, 676, 648 cm−1. 1H NMR (500 MHz,
methanol-d4): δ = 1.11–1.20 (m, 1 H), 1.26–1.40 (m, 4 H),
1.63–2.05 (m, 8 H), 2.11–2.16 (m, 2 H), 2.19–2.28 (m, 1 H),
2.31–2.44 (m, 2 H), 2.47–2.55 (m, 1 H), 2.85–2.91 (m, 1 H),
3.65–3.76 (m, 2 H), 4.15–4.40 (m, 5 H), 7.15–7.23 (m, 3 H),
7.28–7.32 (m, 2 H), 7.37–7.41 (m, 2 H), 7.47 (q, J = 6.6 Hz,
1 H), 7.63–7.69 (m, 2 H), 7.79–7.83 (m, 2 H). 13C NMR and
DEPT (125 MHz, methanol-d4): δ = 26.07 (2 CH2), 26.42
(CH2), 28.11 (CH2), 28.34 (CH2), 29.68 (CH2), 29.89 (CH2),
33.13 (CH2), 34.92 (CH2), 38.88 (CH and CH2), 42.57 (CH2),
54.07 (CH), 54.77 (CH), 66.27 (C), 68.22 (CH2), 117.22 (d, J =
21.2 Hz, CH), 119.65 (d, J = 22.0 Hz, CH), 121.00 (CH),
121.05 (CH), 126.17 (CH), 126.38 (CH), 128.18 (CH), 128.24
(CH), 128.46 (CH), 128.88 (2 CH), 132.01 (CH), 140.54 (C),
142.57 (C), 142.62 (C), 144.97 (C), 145.44 (C), 158.80 (CvO),
164.40 (d, J = 247.3 Hz, C), 168.09 (CvN), 172.49 (2 CvO),
175.41 (CvO). ESI-MS: m/z = 696.5 [M + H]+.
45: EtN(i-Pr)2 (375 μL, 2.21 mmol) was added to a solution
of Fmoc-Glu-OtBu (43) (0.910 g, 2.14 mmol) and HATU
(0.814 g, 2.14 mmol) in CH2Cl2 (50 mL). The mixture was
stirred at room temperature for 10 min and then 4-(tert-butyl-
dimethylsilyloxymethyl)aniline (0.495 g, 2.08 mmol) and EtN-
(i-Pr)2 (375 μL, 2.21 mmol) were added. After stirring at room
temperature for 28 h, the mixture was partitioned between 2%
aqueous citric acid and CH2Cl2, washed with 2% citric acid,
H2O and brine. The organic layer was dried over Na2SO4.
Removal of the solvent and flash chromatography (SiO2;
pentane/ethyl acetate, 10 : 1 to 3 : 7) afforded the amide as a col-
ourless solid, yield: 1.07 g (80%), m.p. 99–100 °C. IR (ATR):
ν = 3326, 2953, 2930, 2888, 2856, 1771, 1733, 1694, 1662,
1601, 1557, 1528, 1452, 1410, 1369, 1338, 1250, 1155, 1081,
1056, 938, 835, 775, 758, 737, 664, 621 cm−1. 1H NMR
(500 MHz, CDCl3): δ = 0.08 (s, 6 H), 0.93 (s, 9 H), 1.46 (s,
9 H), 1.87–1.95 (m, 1 H), 2.27–2.41 (m, 3 H), 4.20 (t, J =
6.8 Hz, 1 H), 4.26–4.30 (m, 1 H), 4.39–4.50 (m, 2 H), 4.68 (s,
2 H), 5.61 (br d, J = 8.2 Hz, 1 H), 7.25–7.33 (m, 4 H),
7.38–7.42 (m, 2 H), 7.55 (d, J = 8.3 Hz, 2 H), 7.60 (t, J =
6.5 Hz, 2 H), 7.77 (dd, J = 7.5, 2.4 Hz, 2 H), 8.29 (br s, 1 H).
13C NMR and DEPT (125 MHz, CDCl3): δ = −5.09 (2 CH3),
18.54 (C), 26.09 (3 CH3), 28.11 (3 CH3), 30.33 (CH2), 34.10
(CH2), 47.33 (CH), 53.85 (CH), 64.78 (CH2), 67.23 (CH2),
83.08 (C), 119.67 (2 CH), 120.14 (CH), 120.18 (CH), 125.15
(CH), 125.26 (CH), 126.87 (2 CH), 127.23 (2 CH), 127.91
(2 CH), 137.11 (C), 137.36 (C), 141.46 (C), 141.49 (C), 143.69
(C), 143.92 (C), 157.03 (CvO), 170.39 (CvO), 171.14
(CvO). ESI-MS: m/z = 645.5 [M + H]+, 662.5 [M + NH4]
+.
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 8216–8235 | 8231
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HF–pyridine (5.0 mL) was added at 0 °C to a solution of this
silyl ether (0.203 g, 0.315 mmol) in THF (10 mL). The reaction
mixture was stirred at 0 °C for 75 min, diluted with ethyl acetate
and neutralised with Na2CO3 (sat. aqueous). The organic layer
was washed with 2% aqueous citric acid, H2O, brine and dried
over Na2SO4. After removal of the solvent, the residue was
purified by flash chromatography (SiO2; petroleum ether/
[CH2Cl2/methanol 10 : 1], 10 : 1 to 1 : 1), affording the alcohol
as a colourless solid, yield: 0.145 g (87%), m.p. 140–142 °C. IR
(ATR): ν = 3311, 3253, 3121, 3058, 2931, 2856, 1695, 1662,
1595, 1534, 1447, 1414, 1367, 1337, 1257, 1227, 1153, 1081,
1054, 1033, 960, 892, 827, 784, 755, 733, 666 cm−1. 1H NMR
(500 MHz, CDCl3): δ = 1.46 (s, 9 H), 1.87–1.95 (m, 1 H),
2.27–2.41 (m, 3 H), 4.18 (t, J = 6.8 Hz, 1 H), 4.25–4.30 (m,
1 H), 4.38–4.49 (m, 2 H), 4.62 (s, 2 H), 5.60 (br d, J = 8.0 Hz,
1 H), 7.29–7.33 (m, 4 H), 7.38–7.42 (m, 2 H), 7.57–7.61 (m,
4 H), 7.77 (dd, J = 7.5, 2.9 Hz, 2 H), 8.35 (br s, 1 H). 13C NMR
and DEPT (125 MHz, CDCl3): δ = 28.12 (3 CH3), 30.39 (CH2),
34.16 (CH2), 47.33 (CH), 53.86 (CH), 65.15 (CH2), 67.26
(CH2), 83.15 (C), 119.92 (2 CH), 120.16 (CH), 120.20 (CH),
125.15 (CH), 125.36 (CH), 127.24 (2 CH), 127.94 (4 CH),
136.74 (C), 137.84 (C), 141.46 (C), 141.48 (C), 143.69 (C),
143.90 (C), 157.07 (CvO), 170.53 (CvO), 171.09 (CvO).
ESI-MS: m/z = 531.5 [M + H]+, 553.5 [M + Na]+.
A mixture of this alcohol (0.599 g, 1.13 mmol) and manga-
nese dioxide (0.981 g, 11.3 mmol) in CH2Cl2 (60 mL) was
stirred at room temperature for 22 h. The reaction mixture was
filtered through a short path of Celite®. After removal of the
solvent, the residue was purified by flash chromatography (SiO2;
petroleum ether/[CH2Cl2/methanol 10 : 1], 10 : 1 to 3 : 1), afford-
ing 45 as a colourless solid, yield: 0.484 g (81%), m.p.
104–105 °C. IR (ATR): ν = 3302, 3061, 2978, 2936, 1718,
1692, 1670, 1590, 1533, 1447, 1414, 1368, 1306, 1260, 1216,
1151, 1102, 1086, 1057, 1031, 963, 829, 734, 642 cm−1. 1H
NMR (300 MHz, CDCl3): δ = 1.46 (s, 9 H), 1.82–1.95 (m, 1 H),
2.28–2.43 (m, 3 H), 4.19–4.29 (m, 2 H), 4.42–4.55 (m, 2 H),
5.63 (br d, J = 8.0 Hz, 1 H), 7.32 (t, J = 7.0 Hz, 2 H), 7.41 (td,
J = 7.4, 2.8 Hz, 2 H), 7.59 (d, J = 7.4 Hz, 2 H), 7.76–7.85 (m,
6 H), 8.98 (br s, 1 H), 9.90 (s, 1 H). 13C NMR and DEPT
(75 MHz, CDCl3): δ = 28.11 (3 CH3), 30.81 (CH2), 34.34
(CH2), 47.34 (CH), 53.68 (CH), 67.41 (CH2), 83.43 (C), 119.39
(2 CH), 120.24 (2 CH), 125.08 (CH), 125.16 (CH), 127.23
(CH), 127.27 (CH), 128.01 (2 CH), 131.26 (2 CH), 132.28 (C),
141.49 (C), 141.54 (C), 143.54 (C), 143.83 (C), 143.99 (C),
157.39 (CO), 170.86 (CvO), 171.04 (CvO), 191.17 (CHO).
ESI-MS: m/z = 529.4 [M + H]+, 546.4 [M + NH4]
+.
46: EtN(i-Pr)2 (468 μL, 2.75 mmol) was added to a solution
of mono-tert-butyl glutarate (0.622 g, 3.30 mmol) and HATU
(1.26 g, 3.31 mmol) in CH2Cl2 (25 mL). The mixture was stirred
at room temperature for 10 min and then 4-(tert-butyldimethyl-
silyloxymethyl)aniline (0.523 g, 2.21 mmol) and EtN(i-Pr)2
(468 μL, 2.75 mmol) were added. After stirring at room tempera-
ture for 24 h, the mixture was partitioned between 2% aqueous
citric acid and CH2Cl2. The organic layer was washed with 2%
citric acid, H2O and brine. The organic layer was dried over
Na2SO4. Removal of the solvent and flash chromatography
(SiO2; pentane/ethyl acetate, 20 : 1 to 3 : 7) afforded the amide as
a colourless, viscous oil, yield: 0.702 g (78%). IR (ATR): ν =
3296, 2954, 2930, 2856, 1727, 1699, 1661, 1602, 1534, 1472,
1458, 1411, 1367, 1309, 1255, 1145, 1083, 1007, 939, 834, 775,
665 cm−1. 1H NMR (500 MHz, CDCl3): δ = 0.08 (s, 6 H), 0.93
(s, 9 H), 1.46 (s, 9 H), 2.01 (quin, J = 7.2 Hz, 2 H), 2.34 (t, J =
7.0 Hz, 2 H), 2.41 (t, J = 7.3 Hz, 2 H), 4.69 (s, 2 H), 7.27 (d,
J = 8.4 Hz, 2 H), 7.48 (d, J = 8.4 Hz, 2 H). 13C NMR and DEPT
(125 MHz, CDCl3): δ = −5.08 (2 CH3), 18.55 (C), 21.25 (CH2),
26.09 (3 CH3), 28.26 (3 CH3), 34.55 (CH2), 36.72 (CH2), 64.78
(CH2), 80.80 (C), 119.74 (2 CH), 126.91 (2 CH), 136.85 (C),
137.46 (C), 170.72 (CvO), 173.01 (CvO). ESI-MS: m/z =
408.3 [M + H]+, 815.7 [2 M + H]+.
TBAF (1 M in THF, 180 μL, 1.80 mmol) was added at 0 °C to
a solution of this amide (0.503 g, 1.23 mmol) in THF (25 mL).
The reaction mixture was stirred at room temperature for 1 h and
then diluted with ethyl acetate. The organic layer was washed
with H2O, brine and dried over Na2SO4. After removal of the
solvent, the residue was purified by flash chromatography (SiO2;
petroleum ether/ethyl acetate, 4 : 1 to 1 : 1), affording the alcohol
as a colourless, viscous oil, yield: 0.348 g (96%). 1H NMR
(500 MHz, CDCl3): δ = 1.45 (s, 9 H), 1.97 (quin, J = 7.2 Hz,
2 H), 2.15 (br s, 1 H), 2.31 (t, J = 7.1 Hz, 2 H), 2.38 (t, J =
7.4 Hz, 2 H), 4.62 (s, 2 H), 7.27 (d, J = 8.4 Hz, 2 H), 7.47 (d,
J = 8.4 Hz, 2 H), 7.81 (br s, 1 H). 13C NMR and DEPT
(125 MHz, CDCl3): δ = 21.20 (CH2), 28.23 (3 CH3), 34.56
(CH2), 36.62 (CH2), 64.97 (CH2), 80.89 (C), 120.11 (2 CH),
127.91 (2 CH), 136.88 (C), 137.49 (C), 171.03 (CvO), 173.11
(CvO). ESI-MS: m/z = 294.2 [M + H]+.
A mixture of this alcohol (0.348 g, 1.19 mmol) and manga-
nese dioxide (1.02 g, 11.7 mmol) in CH2Cl2 (60 mL) was stirred
at room temperature for 22 h. The reaction mixture was filtered
through a short path of Celite®. After removal of the solvent, the
residue was purified by flash chromatography (SiO2; petroleum
ether/ethyl acetate, 4 : 1 to 2 : 1), affording 46 as a colourless
solid, yield: 0.257 g (74%), m.p. 131–132 °C. IR (ATR): ν =
3438, 3326, 3064, 3035, 2952, 2896, 2056, 2030, 1771, 1727,
1699, 1673, 1653, 1581, 1493, 1449, 1401, 1387, 1340, 1223,
1206, 1172, 1017, 1001, 972, 898, 853, 807, 771, 702,
682 cm−1. 1H NMR (500 MHz, CDCl3): δ = 1.46 (s, 9 H), 2.02
(quin, J = 6.7 Hz, 2 H), 2.36 (t, J = 6.9 Hz, 2 H), 2.47 (t, J =
7.3 Hz, 2 H), 7.72 (d, J = 8.6 Hz, 2 H), 7.84 (d, J = 8.6 Hz,
2 H), 8.06 (br s, 1 H), 9.91 (s, 1 H). 13C NMR and DEPT
(125 MHz, CDCl3): δ = 21.04 (CH2), 28.24 (3 CH3), 34.43
(CH2), 36.82 (CH2), 81.10 (C), 119.29 (2 CH), 131.32 (2 CH),
132.27 (C), 143.78 (C), 171.34 (CvO), 173.16 (CvO), 191.23
(CHO). ESI-MS: m/z = 292.1 [M + H]+. Elemental analysis
calcd for C16H21NO2: C 65.96, H 7.27, N 4.81; found: C 66.19,
H 7.40, N 5.04.
47: NaBH(OAc)3 (0.306 g, 1.44 mmol) and a solution of 45
(0.381 g, 0.721 mmol) in 1,2-C2H4Cl2 (8 mL) were added to a
solution of 42 (0.200 g, 0.480 mmol) and EtN(i-Pr)2 (122 μL,
0.717 mmol) in 1,2-C2H4Cl2 (8 mL). The reaction mixture was
stirred for 18 h at room temperature and then partitioned
between Na2CO3 (sat. aqueous) and CH2Cl2. The organic layer
was washed with H2O, brine and dried over Na2SO4. Removal
of the solvent and purification of the residue by flash chromato-
graphy (SiO2; pentane/[CH2Cl2/methanol 10 : 1], 10 : 1 to 2 : 3)
afforded 47 as a colourless solid, yield: 0.289 g (70%), m.p.
114–116 °C. IR (ATR): ν = 3278, 3061, 2930, 2855, 1696,
1687, 1531, 1449, 1368, 1339, 1307, 1243, 1152, 1078, 1046,
893, 844, 824, 781, 738, 696 cm−1. 1H NMR (500 MHz,
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CDCl3): δ = 1.14–1.23 (m, 3 H), 1.32–1.40 (m, 2 H), 1.46 (s, 9
H), 1.58–1.64 (m, 1 H), 1.68–1.72 (m, 2 H), 1.87–1.95 (m, 4
H), 1.99–2.08 (m, 4 H), 2.26–2.43 (m, 4 H), 2.70–2.75 (m, 2
H), 3.47 (s, 2 H), 3.91–3.98 (m, 1 H), 4.17 (t, J = 6.9 Hz, 1 H),
4.26 (t, J = 7.5 Hz, 1 H), 4.36–4.47 (m, 2 H), 5.71 (br d, J = 8.0
Hz, 1 H), 6.94–7.03 (m, 3 H), 7.14 (d, J = 8.3 Hz, 2 H),
7.27–7.41 (m, 5 H), 7.57–7.59 (m, 4 H), 7.76 (d, J = 7.5 Hz,
2 H), 8.04 (br d, J = 7.4 Hz, 1 H), 8.67 (br s, 1 H). 13C NMR
and DEPT (125 MHz, CDCl3): δ = 24.86 (2 CH2), 25.55 (CH2),
28.09 (3 CH3), 30.28 (CH2), 30.66 (2 CH2), 32.88 (2 CH2),
34.08 (CH2), 47.26 (CH), 47.46 (2 CH2), 51.68 (CH), 53.87
(CH), 61.96 (CH2), 64.74 (C), 67.28 (CH2), 83.07 (C), 114.78
(d, J = 20.7 Hz, CH), 117.26 (d, J = 21.9 Hz, CH), 119.88
(2 CH), 120.16 (2 CH), 120.19 (CH), 125.13 (CH), 125.21
(CH), 125.64 (CH), 127.21 (2 CH), 127.93 (2 CH), 129.92
(CH), 130.41 (d, J = 9.4 Hz, CH), 137.90 (d, J = 9.8 Hz, C),
138.18 (C), 141.42 (2 C), 143.63 (C), 143.87 (2 C), 157.08
(CvO), 162.99 (d, J = 247.8 Hz, C), 167.09 (CvN), 170.74
(CvO), 171.04 (CvO), 180.07 (CvO). ESI-MS: m/z = 857.8
[M + H]+.
48: NaBH(OAc)3 (91 mg, 0.429 mmol) and portionwise 46
(63 mg, 0.216 mmol) were added to a solution of 42 (62.5 mg,
0.15 mmol) and EtN(i-Pr)2 (36 μL, 0.212 mmol) in 1,2-C2H4Cl2
(2 mL). The reaction mixture was stirred for 19 h at room temp-
erature and then partitioned between Na2CO3 (sat. aqueous) and
CH2Cl2. The organic layer was washed with H2O, brine and
dried over Na2SO4. Removal of the solvent and purification of
the residue by flash chromatography (SiO2; pentane/[CH2Cl2/
methanol 10 : 1], 20 : 1 to 1 : 1) afforded compound 48 as a col-
ourless solid, yield: 68.3 mg (73%), m.p. 102–104 °C. IR
(ATR): ν = 3263, 3183, 3114, 3058, 2930, 2855, 1723, 1692,
1585, 1530, 1491, 1455, 1396, 1367, 1339, 1308, 1241, 1139,
1079, 1047, 957, 892, 824, 781, 756, 691 cm−1. 1H NMR
(500 MHz, CDCl3): δ = 1.15–1.23 (m, 3 H), 1.32–1.40 (m,
2 H), 1.44 (s, 9 H), 1.61–1.67 (m, 1 H), 1.69–1.74 (m, 2 H),
1.95–2.10 (m, 8 H), 2.30–2.40 (m, 6 H), 2.73–2.78 (m, 2 H),
3.48 (s, 2 H), 3.90–3.96 (m, 1 H), 6.93–7.02 (m, 3 H), 7.15 (d,
J = 8.4 Hz, 2 H), 7.30–7.35 (m, 1 H), 7.52 (d, J = 8.3 Hz, 2 H),
7.99 (br s, 1 H), 8.09 (br d, J = 8.0 Hz, 1 H). 13C NMR and
DEPT (125 MHz, CDCl3): δ = 21.17 (2 CH2), 24.88 (CH2),
25.57 (CH2), 28.22 (3 CH3), 30.72 (2 CH2), 32.88 (2 CH2),
34.58 (CH2), 36.54 (CH2), 47.48 (2 CH2), 51.74 (CH), 61.94
(CH2), 64.75 (C), 80.74 (C), 114.83 (d, J = 20.8 Hz, CH),
117.30 (d, J = 21.8 Hz, CH), 119.91 (2 CH), 125.69 (d, J =
2.7 Hz, CH), 129.92 (2 CH), 130.42 (d, J = 9.3 Hz, CH), 131.61
(C), 137.89 (d, J = 9.7 Hz, C), 138.04 (C), 162.98 (d, J =
247.4 Hz, C), 167.15 (CvN), 171.08 (CvO), 172.98 (CvO),
180.11 (CvO). ESI-MS: m/z = 620.9 [M + H]+.
49: Trifluoroacetic acid (5 mL) was added slowly at 0 °C to a
solution of 47 (50.1 mg, 58.4 μmol) in CH2Cl2 (5 mL). The
mixture was stirred at room temperature for 90 min, diluted with
CH2Cl2 and washed four times with water and once with brine.
Drying over Na2SO4 and removal of the solvent afforded 49 as a
light yellow solid, yield: 36.5 mg (78%), m.p. 156–159 °C. IR
(ATR): ν = 3325, 2930, 2857, 1694, 1662, 1601, 1576, 1529,
1473, 1450, 1411, 1369, 1338, 1249, 1155, 1081, 1055, 1007,
938, 835, 775, 758, 737, 664 cm−1. 1H NMR (500 MHz,
DMSO-d6): δ = 1.07–1.16 (m, 1 H), 1.23–1.32 (m, 5 H), 1.61
(d, J = 12.0 Hz, 1 H), 1.69–1.80 (m, 3 H), 1.84–1.94 (m, 3 H),
1.98–2.09 (m, 4 H), 2.17–2.41 (m, 3 H), 2.68–2.77 (m, 3 H),
3.45–3.51 (m, 1 H), 3.60–3.69 (m, 2 H), 3.94–4.00 (m, 1 H),
4.14–4.30 (m, 2 H), 7.18–7.33 (m, 6 H), 7.39–7.49 (m, 4 H),
7.63 (t, J = 7.1 Hz, 2 H), 7.69–7.72 (m, 2 H), 7.89 (d, J =
7.6 Hz, 2 H), 8.14 (m, 1 H), 12.62 (br s, 1 H). HPLC ret. time =
14.9 min, 99.9%. ESI-MS: m/z = 801.7 [M + H]+.
50: A mixture of 48 (57.3 mg, 92.5 μmol), silica gel (0.570 g)
and toluene (15 mL) was stirred at reflux for 6 h. The reaction
mixture was diluted with CH2Cl2/methanol (10 : 1) and filtered
through a short path of Celite®. After removal of the solvent 50
was obtained as a light yellow solid, yield: 44.8 mg (86%), m.p.
143–146 °C. IR (ATR): ν = 3261, 3051, 2926, 2854, 1700,
1587, 1530, 1490, 1402, 1336, 1249, 1134, 1092, 1072, 1005,
938, 893, 833, 767 cm−1. HPLC ret. time = 6.6 min, 97.3%.
ESI-MS: m/z = 562.2 [M − H]−.
51: Compound 49 (51.4 mg, 64.2 μmol) was dissolved in
DMF (5 mL), piperidine (1 mL) was added and the reaction
mixture was stirred at room temperature for 3.5 h. After complete
removal of the solvent, the residue was washed twice with
diethyl ether (1 mL) and taken up in the minimal volume of
methanol. The product was precipitated by dropwise addition to
diethyl ether (100 mL), filtered and dried. 51 was obtained as a
colourless solid, yield: 27.7 mg (75%), m.p. 178–180 °C. IR
(ATR): ν = 3316, 3064, 2930, 2856, 1693, 1600, 1531, 1515,
1473, 1451, 1410, 1366, 1338, 1308, 1249, 1155, 1080, 1051,
1006, 937, 892, 836, 776, 758, 739, 664 cm−1. 1H NMR
(500 MHz, CDCl3/methanol-d4, 3 : 1): δ = 1.03–1.26 (m, 6 H),
1.45–1.52 (m, 2 H), 1.56–1.64 (m, 3 H), 1.79 (br d, J = 10.1 Hz,
2 H), 1.89–2.07 (m, 8 H), 2.40–2.43 (m, 2 H), 2.64 (br s, 2 H),
3.15 (s, 2 H), 3.31 (br s, 2 H), 3.40 (t, J = 5.8 Hz, 1 H), 3.61 (br
s,1 H), 6.74 (dt, J = 9.5, 2.2 Hz, 1 H), 6.80 (d, J = 7.9 Hz, 1 H),
6.88–6.94 (m, 3 H), 7.15–7.20 (m, 1 H), 7.33 (d, J = 8.5 Hz,
2 H). HPLC ret. time = 3.2 min, 99.9%. ESI-MS: m/z = 579.5
[M + H]+.
Typical procedure for the preparation of the peptides
H-Glu-Val-Asn-Sta-Val-Ala-Glu-Phe-4Gl-3Gl-4Gl-3Gl-4Gl-Asp-
(ODhc)-NH2 (6a), where Sta is (3S,4S)-4-amino-3-hydroxy-6-
methylheptanoic acid. Loading and automated assembly of Asp
(ODhc)14 to Glu1: the PAL-PEG-PS resin (0.38 mmol g−1,
0.30 mmol) was subjected to automated deprotection, and
loaded with Fmoc-Asp(ODhc)-OH, which was automatically
activated and coupled. While the majority of the amino acids
was coupled using the standard cycle as described above, the
building blocks 4d–g, 24, 28, 32, 33, 41, 44, 49 and 50 were
manually activated: the amino acid (2 equiv. based on the resin)
was dissolved in DMF (2 mL). HATU (2 equiv. based on the
resin) and EtN(i-Pr)2 (2 equiv. based on the resin) were added
and the mixture was stirred at room temperature for 10 min.
Then EtN(i-Pr)2 (2 equiv. based on the resin) was added and the
mixture was transferred to the synthesiser, where coupling,
washing and deprotection took place. Cleavage and post-
cleavage processing: after washing with CH2Cl2 and drying in
vacuo, the peptide was cleaved by stirring in CF3COOH/
(i-Pr)3SiH/H2O (95 : 2.5 : 2.5) at room temperature for 90 min.
After removal of the resin by filtration, the crude peptide was
collected by precipitation from pentane/diethyl ether (1 : 1) at
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 8216–8235 | 8233
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−78 °C and subsequent centrifugation. The centrifugate was dis-
solved in methanol/acetonitrile/H2O/AcOH (20 : 20 : 10 : 1). Pre-
parative HPLC with a gradient from 50% to 85% of eluent B in
20 min (product ret. time: 18.4 min) afforded after drying 6a as
a colourless lacquer, yield: 0.174 g (57%). HPLC ret. time =
27.5 min, 99.9%. ESI-MS: m/z = 2596.5 [M + H]+, 2614.4
[M + NH4]
+, 2619.5 [M + Na]+.
Cell culture
An SH-SY5Y cell line stably overexpressing wild-type APP695
with an N-terminal Myc tag and a C-terminal Flag tag46 was
kindly provided by L. Münter and G. Multhaup (Freie Universi-
tät Berlin). The cells were cultured in D-MEM/F12, sup-
plemented with 10% fetal calf serum, 2 mM L-glutamine, non-
essential amino acids and 50 μg mL−1 hygromycin B. Cultures
were grown at 37 °C, 5% CO2.
Inhibitor treatments
The test compounds were initially dissolved in DMSO at con-
centrations of 5 or 10 mM and stored in aliquots at −20 °C. For
the cell culture experiments, compound dilutions (100× of the
desired final concentration in the test) were prepared in 100%
DMSO, and were freshly diluted 1 : 100 with cell culture
medium. The final concentration of DMSO in the experiments
and controls was 1%. The culture medium in the cell culture
plates was replaced with the fresh medium containing the com-
pounds or 1% DMSO (blank test). For the ECL measurements
SH-SY5Y cells were seeded 24 h before treatment in 96 well
cell culture plates at a cell density of 2 × 105 cells cm−2. The
compounds were diluted in the medium and added to the cells as
described above. For each condition six wells were used and
pooled after an incubation time of 4–5 h.
Electrochemiluminescence (ECL) assay
Aβ-peptides in cell supernatants were measured with the MSD®
Human (6E10) Abeta 40 Kit according to the manufacturer’s
protocol on a Sector™ Imager 6000 (Meso Scale Discovery).
The synthetic reference peptide dilutions were prepared in 1%
blocker A. The fetal calf serum present in the SH-SY5Y cell
culture medium contains bovine Aβ-peptides which are detected
by the ECL assay. The amount of the bovine Aβ40 in an uncon-
ditioned culture medium was determined to be ∼50 pg mL−1,
and this background value was subtracted from the calculated Aβ
concentrations in the SH-SY5Y cell culture experiments.
Dose–response curves and EC50 determinations
For the calculation of dose–response curves and EC50 values for
SH-SY5YAPPwt cells, all compounds were tested in three inde-
pendent experiments in approximately half-logarithmic serial
dilutions. For six compounds (6d, 6e, 7m, 16, 19 and 20),
ranges of inhibitor concentrations were altered in different exper-
iments in order to define both top and bottom plateaus of the
dose–response curve. Therefore, not each single concentration
was analysed in all three experiments. Error bars in the
corresponding graphs represent data from at least two exper-
iments. For four other compounds (free pharmacophores 41, 17,
51 and anchor variant 6g), at least two experiments were con-
ducted over the full concentration range (nine inhibitor dilutions
and DMSO control), while in a third experiment a reduced
number of concentrations was used to confirm the EC50. After
4–5 h incubation at 37 °C and 5% CO2, the cell culture super-
natants from 6 wells of a 96 well culture plate were pooled and
measured in duplicate with the Aβ40 ECL assay. The signals
were normalised to % of the DMSO controls. Means of the nor-
malised duplicate values were plotted against inhibitor concen-
tration and the log EC50 values were calculated by non-linear
regression using GraphPad Prism 5.01 software (GraphPad Soft-
ware Inc., La Jolla, USA).
Statistical analysis
Statistical analysis was performed with the GraphPad Prism Soft-
ware, version 5.01. The initial result obtained from curve fitting
by non-linear regression is the log EC50 of the compound (not
the EC50, which is calculated in a second step). To compare the
potency of different compounds, the respective log EC50 values
from at least 3 independent experiments were averaged and sub-
jected to statistical tests. For two compounds, Student’s t-test
(two-tailed, unpaired) was used to compare means and variations
of log EC50 values, while a one-way ANOVAwas employed for
comparison of three or more compounds. In this case, either
Dunnett’s (comparison of all compounds to one reference com-
pound) or Tukey’s (pairwise comparison of all compounds)
post-test was added to correct for multiple testing. In our pre-
vious publication,26 we pooled normalised values from three
independent measurements to calculate the EC50 by non-linear
regression from the pooled dataset. This method leads to slightly
different EC50 values. In this study, pooled datasets were used
only for the representation of dose–response curves in graphs,
allowing a more clear visualisation. For all statistical analyses,
log EC50 means and standard deviations from three independent
measurements were used, because this method facilitates com-
parison of multiple compounds. A comparison of log EC50 and
de-logarithmised EC50 values calculated by averaging values
from three or more experiments with EC50 values obtained by
non-linear regression analysis of pooled datasets revealed very
small differences (ESI, Table S2†).
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